<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="review-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">QGjZYVrJPfCnSPfCKzpZkQy</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2012000300011</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(12)09800311</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2012000300011</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo de Revis&#227;o</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Altera&#231;&#245;es gastrointestinais associadas a insufici&#234;ncia card&#237;aca</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Romeiro</surname>
            <given-names>Fernando G.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Okoshi</surname>
            <given-names>Katashi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zornoff</surname>
            <given-names>Leonardo A. M.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Okoshi</surname>
            <given-names>Marina P.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade Estadual Paulista</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>03</month>
        <year>2012</year>
      </pub-date>
      <volume>98</volume>
      <issue>3</issue>
      <fpage>273</fpage>
      <lpage>277</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>06</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>12</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>06</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Na &#250;ltima d&#233;cada, foram realizados v&#225;rios estudos sobre altera&#231;&#245;es gastrointestinais associadas a insufici&#234;ncia card&#237;aca cr&#244;nica. Neste artigo, apresentamos revis&#227;o da literatura sobre a fisiopatologia e consequ&#234;ncias cl&#237;nicas das altera&#231;&#245;es patol&#243;gicas digestivas de pacientes com insufici&#234;ncia card&#237;aca. Anormalidades estruturais e funcionais do trato gastrointestinal, como edema da mucosa absortiva e hipercrescimento bacteriano intestinal, t&#234;m sido responsabilizadas por graves consequ&#234;ncias cl&#237;nicas. Entre essas, destacam-se caquexia card&#237;aca, ativa&#231;&#227;o inflamat&#243;ria sist&#234;mica e anemia. Essas condi&#231;&#245;es, isoladamente ou em combina&#231;&#227;o, podem levar a piora da disfun&#231;&#227;o ventricular preexistente. Embora atualmente n&#227;o haja terap&#234;utica espec&#237;fica direcionada &#224;s altera&#231;&#245;es gastrointestinais associadas a insufici&#234;ncia card&#237;aca, o entendimento das anormalidades digestivas &#233; fundamental para sua preven&#231;&#227;o e manejo das consequ&#234;ncias sist&#234;micas.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Insufici&#234;ncia card&#237;aca</kwd>
        <kwd>caquexia</kwd>
        <kwd>anormalidades do sistema digest&#243;rio</kwd>
        <kwd>absor&#231;&#227;o intestinal</kwd>
        <kwd>anemia</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>23</day>
        <month>04</month>
        <year>2012</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO DE REVIS&#195;O</bold>
    </p>
    <p>
      <bold>Altera&#231;&#245;es gastrointestinais associadas a insufici&#234;ncia card&#237;aca</bold>
    </p>
    <p>
      <bold>Fernando G. Romeiro; Katashi Okoshi; Leonardo A. M. Zornoff; Marina P. Okoshi</bold>
    </p>
    <p>Faculdade de Medicina de Botucatu, SP, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="not">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>Na &#250;ltima d&#233;cada, foram realizados v&#225;rios estudos sobre altera&#231;&#245;es gastrointestinais associadas a insufici&#234;ncia card&#237;aca cr&#244;nica. Neste artigo, apresentamos revis&#227;o da literatura sobre a fisiopatologia e consequ&#234;ncias cl&#237;nicas das altera&#231;&#245;es patol&#243;gicas digestivas de pacientes com insufici&#234;ncia card&#237;aca. Anormalidades estruturais e funcionais do trato gastrointestinal, como edema da mucosa absortiva e hipercrescimento bacteriano intestinal, t&#234;m sido responsabilizadas por graves consequ&#234;ncias cl&#237;nicas. Entre essas, destacam-se caquexia card&#237;aca, ativa&#231;&#227;o inflamat&#243;ria sist&#234;mica e anemia. Essas condi&#231;&#245;es, isoladamente ou em combina&#231;&#227;o, podem levar a piora da disfun&#231;&#227;o ventricular preexistente. Embora atualmente n&#227;o haja terap&#234;utica espec&#237;fica direcionada &#224;s altera&#231;&#245;es gastrointestinais associadas a insufici&#234;ncia card&#237;aca, o entendimento das anormalidades digestivas &#233; fundamental para sua preven&#231;&#227;o e manejo das consequ&#234;ncias sist&#234;micas. </p>
    <p><bold>Palavras-chave:</bold> Insufici&#234;ncia card&#237;aca/complica&#231;&#245;es, caquexia, anormalidades do sistema digest&#243;rio, absor&#231;&#227;o intestinal, anemia</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A Insufici&#234;ncia Card&#237;aca (IC) pode ser definida como s&#237;ndrome cl&#237;nica complexa que se origina de anormalidades card&#237;acas estruturais e/ou funcionais, adquiridas ou heredit&#225;rias, que levam a piora da capacidade de enchimento e eje&#231;&#227;o ventricular<sup>1</sup>. Constitui um problema cl&#237;nico de extrema import&#226;ncia, tanto por sua alta preval&#234;ncia como pela gravidade de suas manifesta&#231;&#245;es cl&#237;nicas. No Brasil, &#233; a terceira causa mais frequente de interna&#231;&#227;o hospitalar e a primeira causa de interna&#231;&#227;o por doen&#231;a cardiovascular. Segundo dados do Datasus, em 2003 ocorreram mais de 350 mil interna&#231;&#245;es por IC no pa&#237;s<sup>2</sup>.</p>
    <p>As causas mais comuns de IC s&#227;o isquemia mioc&#225;rdica, hipertens&#227;o arterial sist&#234;mica, miocardiopatias e valvopatias. Em muitos casos, por&#233;m, a etiologia permanece obscura.</p>
    <p>A partir dos estudos pioneiros de Frank, em 1895, e Starling, em 1918, surgiu o conceito de que altera&#231;&#245;es na fun&#231;&#227;o de relaxamento e eje&#231;&#227;o do cora&#231;&#227;o s&#227;o respons&#225;veis pelo desenvolvimento e progress&#227;o da IC. Entretanto, nas &#250;ltimas d&#233;cadas, ficou claro que a IC &#233; uma s&#237;ndrome muito mais complexa envolvendo n&#227;o somente o sistema cardiovascular, mas tamb&#233;m os sistemas renal, neuroendocrinol&#243;gico, imunol&#243;gico, musculoesquel&#233;tico, hematol&#243;gico e gastrointestinal. Portanto, pesquisas t&#234;m sido desenvolvidas para elucidar a fisiopatologia de complica&#231;&#245;es sist&#234;micas e propor tratamento que promova melhora da qualidade e da expectativa de vida de pacientes com a doen&#231;a. Entre essas, destacam-se os estudos sobre o comprometimento do Trato Gastrointestinal (TGI) na IC.</p>
    <p>Nesta revis&#227;o mostraremos as altera&#231;&#245;es estruturais e funcionais que podem ocorrer no TGI de pacientes com IC. A seguir, apresentaremos as manifesta&#231;&#245;es decorrentes do comprometimento do TGI, com particular &#234;nfase na absor&#231;&#227;o inadequada de constituintes bacterianos. Finalmente, vamos abordar estrat&#233;gias atuais e sob investiga&#231;&#227;o para prevenir e/ou tratar altera&#231;&#245;es do TGI associadas &#224; IC e suas consequ&#234;ncias sist&#234;micas.</p>
    <p>O comprometimento do TGI na IC come&#231;ou a ser estudado na d&#233;cada de 1960 por Davidson e cols.<sup>3</sup>. Os autores mostraram que pacientes com pericardite constritiva apresentavam gastroenteropatia perdedora de prote&#237;nas, revers&#237;vel ap&#243;s corre&#231;&#227;o cir&#250;rgica da les&#227;o card&#237;aca. Apesar dos estudos iniciais, somente na &#250;ltima d&#233;cada o TGI passou a ser avaliado mais detalhadamente na IC.</p>
    <p>
      <bold>Altera&#231;&#245;es gastrointestinais estruturais associadas a IC</bold>
    </p>
    <p>Diversas altera&#231;&#245;es estruturais t&#234;m sido descritas no TGI de pacientes com IC. No est&#244;mago, foram observadas anormalidades da mucosa g&#225;strica como padr&#227;o "em mosaico", ectasia vascular antral, espessamento mucoso e &#225;reas de telangiectasias<sup>4,5</sup>.</p>
    <p>No &#237;leo terminal, c&#243;lon e sigmoide, foi observado, por ultrassonografia, aumento da espessura da parede intestinal, sugerindo a presen&#231;a de edema de al&#231;as nos pacientes com IC<sup>6</sup>. Embora h&#225; muito se acreditasse que h&#225; edema de parede intestinal em doentes com reten&#231;&#227;o h&#237;drica importante, esse foi o primeiro relato da altera&#231;&#227;o documentada por exame de imagem realizado <italic>in vivo</italic>. A espessura da parede do sigmoide parece ter implica&#231;&#245;es cl&#237;nicas, uma vez que suas medidas foram positivamente correlacionados com a concentra&#231;&#227;o sangu&#237;nea de leuc&#243;citos e de Prote&#237;na C Reativa (PCR) ultrassens&#237;vel<sup>6</sup>. Esses resultados sugerem que as altera&#231;&#245;es intestinais tenham relev&#226;ncia na indu&#231;&#227;o de inflama&#231;&#227;o sist&#234;mica, como veremos posteriormente. Al&#233;m de espessada, a parede intestinal do intestino delgado apresenta aumento do conte&#250;do de tecido col&#225;geno, que &#233; proporcional &#224; gravidade da IC<sup>7</sup>. Provavelmente, como consequ&#234;ncia dessas altera&#231;&#245;es, a dist&#226;ncia entre a l&#226;mina basal do enter&#243;cito e o capilar sangu&#237;neo encontra-se aumentada<sup>7</sup>. Atualmente, acredita-se que as altera&#231;&#245;es estruturais sejam respons&#225;veis por piora da nutri&#231;&#227;o do enter&#243;cito e, consequentemente, por anormalidades da absor&#231;&#227;o intestinal associadas a IC.</p>
    <p>
      <bold>Altera&#231;&#245;es gastrointestinais funcionais associadas a IC</bold>
    </p>
    <p>Em condi&#231;&#245;es fisiol&#243;gicas, a circula&#231;&#227;o espl&#226;ncnica recebe aproximadamente 25% do d&#233;bito card&#237;aco, fazendo que o intestino seja um dos &#243;rg&#227;os mais intensamente perfundidos em repouso<sup>8</sup>. A circula&#231;&#227;o espl&#226;ncnica &#233; ricamente suprida com nervos simp&#225;ticos. Consequentemente, o aumento da atividade do sistema nervoso simp&#225;tico leva &#224; constri&#231;&#227;o dos vasos de resist&#234;ncia pr&#233;-capilares e dos vasos de capacit&#226;ncia p&#243;s-capilares, com redu&#231;&#227;o da perfus&#227;o sangu&#237;nea. As altera&#231;&#245;es vasculares intestinais podem preceder varia&#231;&#245;es na frequ&#234;ncia card&#237;aca ou press&#227;o arterial<sup>9</sup>. Portanto, mesmo redu&#231;&#245;es discretas do d&#233;bito card&#237;aco podem levar a diferentes graus de isquemia intestinal. Em pacientes com IC avan&#231;ada, Krack e cols.<sup>10</sup> observaram acidose intramucosa no est&#244;mago induzida por leve atividade f&#237;sica, documentando, portanto, a ocorr&#234;ncia de hipoperfus&#227;o do TGI. </p>
    <p>As altera&#231;&#245;es funcionais envolvem, basicamente, anormalidades da permeabilidade intestinal. A absor&#231;&#227;o intestinal ocorre por via transcelular, na qual os constituintes dos alimentos s&#227;o absorvidos para o interior do enter&#243;cito e, a seguir, para o capilar sangu&#237;neo, e por via paracelular, na qual s&#227;o absorvidos passivamente por passagem entre os enter&#243;citos<sup>5</sup>. A via de absor&#231;&#227;o paracelular pode ser avaliada por testes com administra&#231;&#227;o de a&#231;&#250;cares e posterior an&#225;lise de suas concentra&#231;&#245;es na urina<sup>6</sup>. Tanto no intestino delgado como nos c&#243;lons, a absor&#231;&#227;o paracelular independente de prote&#237;nas carreadoras encontra-se aumentada na IC, sugerindo ruptura da barreira intestinal<sup>5,6</sup>. Por sua vez, o transporte passivo mediado por prote&#237;nas carreadoras do intestino delgado encontra-se reduzido na IC, sugerindo d&#233;ficit de ATP para a microcircula&#231;&#227;o<sup>6</sup>.</p>
    <p>Em 1996, King e cols.<sup>11</sup> observaram que pacientes com IC e caquexia apresentavam redu&#231;&#227;o da absor&#231;&#227;o intestinal de gorduras, quando comparados com doentes sem caquexia ou indiv&#237;duos saud&#225;veis. A diminui&#231;&#227;o da absor&#231;&#227;o intestinal foi bem documentada em trabalho recente, no qual se observou maior perda de prote&#237;nas e gorduras nas fezes de pacientes com IC em classes funcionais III e IV do que naqueles em classes I e II<sup>7</sup>. Adicionalmente, a redu&#231;&#227;o da absor&#231;&#227;o intestinal foi mais evidente nos doentes com caquexia card&#237;aca. Assim, as evid&#234;ncias sugerem que altera&#231;&#245;es da absor&#231;&#227;o intestinal possam estar envolvidas na etiologia da caquexia associada a IC<sup>12</sup>.</p>
    <p>Al&#233;m das altera&#231;&#245;es na absor&#231;&#227;o, pacientes com IC exibem alto &#237;ndice de coloniza&#231;&#227;o bacteriana intestinal. Pela t&#233;cnica de FISH (Fluorescence In Situ Hybridization), foi poss&#237;vel mostrar que a concentra&#231;&#227;o de bact&#233;rias no biofilme mucoso e a extens&#227;o de sua ader&#234;ncia &#224; parede do sigmoide est&#227;o aumentadas na IC<sup>6</sup>. Atualmente, acredita-se que o aumento da coloniza&#231;&#227;o bacteriana intestinal seja decorrente das altera&#231;&#245;es estruturais e funcionais do TGI, provavelmente em combina&#231;&#227;o com anormalidades imunol&#243;gicas associadas a IC. </p>
    <p>Uma das principais consequ&#234;ncias das altera&#231;&#245;es gastrointestinais &#233; a absor&#231;&#227;o inadequada de constituintes bacterianos, particularmente de endotoxinas, tamb&#233;m conhecidas como lipopolissac&#225;rides<sup>5</sup>. As endotoxinas constituem componente t&#243;xico e imunog&#234;nico de bact&#233;rias Gram-negativas. Apesar das dificuldades para a dosagem de endotoxinas, Niebauer e cols.<sup>13</sup> mostraram que pacientes com IC e edema t&#234;m aumento da concentra&#231;&#227;o plasm&#225;tica de endoxinas quando comparados &#224;queles sem edema. Adicionalmente, foi observado que, ap&#243;s terapia com diur&#233;ticos, ocorre normaliza&#231;&#227;o da concentra&#231;&#227;o s&#233;rica de endotoxinas<sup>13</sup>. Esse estudo foi importante para refor&#231;ar hip&#243;tese vigente de que o edema da parede intestinal estaria envolvido na altera&#231;&#227;o da permeabilidade intestinal e absor&#231;&#227;o inadequada de constituintes bacterianos. O edema intestinal, com suas consequ&#234;ncias sist&#234;micas, parece caracterizar a principal diferen&#231;a, em rela&#231;&#227;o ao comprometimento do TGI, entre a IC cr&#244;nica, est&#225;vel, e a IC descompensada. </p>
    <p>Atualmente, os lipopolissac&#225;rides s&#227;o considerados um dos mais potentes indutores do fator de necrose tumoral (TNF)-&#945; e de outras subst&#226;ncias pr&#243;-inflamat&#243;rias.</p>
    <p>A import&#226;ncia do TNF-&#945; na IC foi primeiramente descrita por Levine e cols.<sup>14</sup>, em 1990. Os autores observaram que pacientes com IC apresentavam n&#237;veis s&#233;ricos elevados do TNF-&#945; e esses eram particularmente maiores naqueles com caquexia. Os achados foram marcantes no entendimento da fisiopatologia da IC e suas complica&#231;&#245;es e desencadearam substancial quantidade de pesquisa nessa &#225;rea<sup>15,16</sup>. Logo tornou-se claro que o TNF-&#945; &#233; um bom marcador da gravidade na IC, correlacionando-se com a sobrevida, a classe funcional da IC, a <italic>performace</italic> card&#237;aca e a concentra&#231;&#227;o s&#233;rica do pept&#237;deo natriur&#233;tico cerebral<sup>17-20</sup>. Em estudos experimentais, o aumento de TNF-&#945;, induzido por administra&#231;&#227;o ex&#243;gena ou por aumento da express&#227;o g&#234;nica, leva ao fen&#243;tipo da IC, caracterizado por remodela&#231;&#227;o ventricular e redu&#231;&#227;o da sobrevida<sup>21,22</sup>. Esses achados permitiram chegar &#224; conclus&#227;o que o TNF-&#945; n&#227;o &#233; apenas marcador de gravidade, mas tamb&#233;m indutor de IC e de piora do quadro de disfun&#231;&#227;o ventricular. Posteriormente, foi verificado que, al&#233;m do TNF-&#945;, outras citocinas tamb&#233;m est&#227;o aumentadas na IC.</p>
    <p>As fontes produtoras de citocinas ainda n&#227;o est&#227;o completamente esclarecidas. O pr&#243;prio mioc&#225;rdio, estruturalmente lesado, pode expressar e produzir n&#237;veis aumentados de mediadores inflamat&#243;rios, como mol&#233;culas de ades&#227;o, TNF-&#945; e IL-6. Leuc&#243;citos circulantes, plaquetas, c&#233;lulas endoteliais, e c&#233;lulas do pulm&#227;o e do f&#237;gado tamb&#233;m parecem estar envolvidos na produ&#231;&#227;o de citocinas. &#201; importante salientar que a resposta inflamat&#243;ria n&#227;o depende da etiologia da IC, ocorrendo como uma via final comum no portador de IC, independentemente da causa da doen&#231;a<sup>23</sup>. Entre os mecanismos propostos na g&#234;nese da produ&#231;&#227;o de citocinas, destacam-se a sobrecarga hemodin&#226;mica, ativa&#231;&#227;o neuro-hormonal, presen&#231;a de hipoxemia e hipoperfus&#227;o tecidual, oxida&#231;&#227;o de lipoprote&#237;nas de baixa densidade, presen&#231;a de autoanticorpos e estimula&#231;&#227;o imunol&#243;gica causada por agentes microbianos, especialmente as endotoxinas<sup>23</sup>. </p>
    <p>Atualmente, considera-se que um dos principais est&#237;mulos para a produ&#231;&#227;o de citocinas na IC seja a absor&#231;&#227;o de endotoxinas provenientes do TGI<sup>23</sup>. Redu&#231;&#227;o da produ&#231;&#227;o intracelular de citocinas ap&#243;s seletiva descontamina&#231;&#227;o intestinal com antibi&#243;tico refor&#231;a a hip&#243;tese<sup>13,24</sup>. As endotoxinas podem ser inativadas pelo colesterol s&#233;rico, que forma micelas ao seu redor, aprisionando-as em seu interior. Esse fato tem sido usado para explicar por que pacientes com IC e colesterol elevado t&#234;m melhor sobrevida que aqueles com colesterol reduzido. Segundo a teoria, maiores concentra&#231;&#245;es s&#233;ricas de colesterol implicariam maior neutraliza&#231;&#227;o de endotoxinas<sup>25,26</sup>. Mais recentemente, foi observado que o aumento da concentra&#231;&#227;o s&#233;rica de TNF-&#945; induz altera&#231;&#245;es adicionais na barreira epitelial intestinal<sup>9,12</sup>. Forma-se, assim, ciclo vicioso no qual o aumento da concentra&#231;&#227;o s&#233;rica de uma citocina facilita a absor&#231;&#227;o de endotoxinas que, por sua vez, induzem a produ&#231;&#227;o de v&#225;rias citocinas.</p>
    <p>Pode-se concluir, portanto, que a IC induz anormalidades estruturais e funcionais no TGI. Uma das consequ&#234;ncias mais importantes do comprometimento do TGI &#233; a altera&#231;&#227;o da absor&#231;&#227;o intestinal, levando a comprometimento do estado nutricional e a ativa&#231;&#227;o imunol&#243;gica<sup>9,12</sup>.</p>
    <p>
      <bold>Consequ&#234;ncias das altera&#231;&#245;es gastrointestinais associadas a IC</bold>
    </p>
    <p>
      <bold>Anemia</bold>
    </p>
    <p>Em meta-an&#225;lise recentemente publicada, que incluiu mais de 153 mil pacientes com IC, a preval&#234;ncia de anemia foi de 37,2%<sup>27</sup>. Diversos fatores podem estar envolvidos na etiologia da anemia, como diminui&#231;&#227;o da ingest&#227;o alimentar, redu&#231;&#227;o da absor&#231;&#227;o intestinal, perdas sangu&#237;neas pelo TGI, anormalidades na produ&#231;&#227;o de hem&#225;cias, piora da fun&#231;&#227;o renal, inflama&#231;&#227;o cr&#244;nica, hemodilui&#231;&#227;o e uso de medicamentos<sup>28</sup>. A seguir, vamos discorrer, resumidamente, sobre fatores etiol&#243;gicos envolvidos na g&#234;nese da anemia associada a IC que s&#227;o decorrentes, pelo menos parcialmente, de anormalidades do TGI.</p>
    <p>O componente "carencial" parece ter papel importante no desenvolvimento da anemia. Esse decorre de tr&#237;ade de altera&#231;&#245;es comumente encontradas na IC: redu&#231;&#227;o da ingest&#227;o alimentar, diminui&#231;&#227;o da absor&#231;&#227;o intestinal e perdas sangu&#237;neas pelo TGI<sup>28</sup>. Como em outras doen&#231;as cr&#244;nicas, na IC h&#225; ativa&#231;&#227;o de mecanismos envolvidos na redu&#231;&#227;o da absor&#231;&#227;o de ferro. Os lipopolissac&#225;rides, assim como a IL-6, induzem a produ&#231;&#227;o hep&#225;tica de hepcidina, prote&#237;na de fase aguda que reduz a absor&#231;&#227;o gastrointestinal de ferro, levando &#224; diminui&#231;&#227;o do ferro s&#233;rico, condi&#231;&#227;o denominada defici&#234;ncia real de ferro. Adicionalmente, a hepcidina reduz a libera&#231;&#227;o de ferro dos estoques de macr&#243;fagos e hepat&#243;citos, colaborando, tamb&#233;m, para a redu&#231;&#227;o do ferro s&#233;rico, nesse caso denominada defici&#234;ncia funcional de ferro<sup>29</sup>. Outro fator que pode induzir anemia &#233; a perda sangu&#237;nea pelo TGI. Muitos pacientes com IC fazem uso de antiagregantes plaquet&#225;rios como o &#225;cido acetilsalic&#237;lico e/ou anticoagulantes. Esses medicamentos podem tanto causar les&#245;es de mucosa em diversas partes do TGI como facilitar a perda sangu&#237;nea pelo tubo digestivo<sup>28</sup>.</p>
    <p>A defici&#234;ncia de ferro, al&#233;m de inibir a eritropoese, pode induzir altera&#231;&#245;es card&#237;acas adicionais, uma vez que est&#225; associada &#224; ativa&#231;&#227;o do sistema nervoso simp&#225;tico, dilata&#231;&#227;o ventricular, altera&#231;&#245;es mitocondriais card&#237;acas e trombocitose. As anormalidades associadas &#224; ferrodefici&#234;ncia podem ser revers&#237;veis com a administra&#231;&#227;o de ferro. H&#225; relatos de que a reposi&#231;&#227;o de ferro pode, at&#233; mesmo, inibir a produ&#231;&#227;o de TNF-&#945;<sup>30,31</sup>.</p>
    <p>Embora n&#227;o tenha sido sistematicamente avaliada em grandes estudos, defici&#234;ncia de ferro foi relatada em 1% a 44 % dos casos, dependendo da gravidade da IC e da popula&#231;&#227;o estudada<sup>32,33</sup>. Em pacientes com IC grave, defici&#234;ncia de ferro foi a causa mais frequente de anemia, sendo respons&#225;vel por 73% dos casos<sup>34</sup>. Muitos autores acreditam, por&#233;m, que, ap&#243;s corre&#231;&#227;o da ferrodefici&#234;ncia, os pacientes passem a manifestar o componente da doen&#231;a inflamat&#243;ria como respons&#225;vel pela anemia.</p>
    <p>
      <bold>Caquexia</bold>
    </p>
    <p>Outra consequ&#234;ncia sist&#234;mica decorrente, pelo menos em parte, de altera&#231;&#245;es do TGI e da ativa&#231;&#227;o imunol&#243;gica durante a IC &#233; a caquexia. Atualmente, a caquexia &#233; considerada um fator preditivo de redu&#231;&#227;o da sobrevida de pacientes com IC, independentemente de vari&#225;veis importantes como idade, classe funcional da IC ou fra&#231;&#227;o de eje&#231;&#227;o<sup>35</sup>. </p>
    <p>Embora a fisiopatologia da caquexia associada a IC n&#227;o esteja ainda completamente esclarecida, diversos fatores t&#234;m sido responsabilizados pelo seu desenvolvimento como diminui&#231;&#227;o da ingest&#227;o alimentar, redu&#231;&#227;o da absor&#231;&#227;o intestinal de nutrientes, aumento do gasto energ&#233;tico basal e altera&#231;&#245;es imunol&#243;gicas e neuroendocrinol&#243;gicas<sup>36,37</sup>.</p>
    <p>A caquexia est&#225; associada a diversas complica&#231;&#245;es sist&#234;micas, dentre as quais se destacam as altera&#231;&#245;es card&#237;acas e da musculatura esquel&#233;tica. &#201; dif&#237;cil avaliar o comprometimento espec&#237;fico da caquexia sobre o cora&#231;&#227;o, uma vez que essa ocorre no contexto de doen&#231;a inflamat&#243;ria cr&#244;nica e, como j&#225; referido, a ativa&#231;&#227;o imunol&#243;gica leva a importantes efeitos delet&#233;rios no cora&#231;&#227;o<sup>12</sup>. Em nosso laborat&#243;rio, avaliamos os efeitos isolados da restri&#231;&#227;o da ingest&#227;o alimentar sobre cora&#231;&#245;es de ratos normotensos e hipertensos. A redu&#231;&#227;o do peso corporal levou &#224; diminui&#231;&#227;o da massa muscular card&#237;aca, que foi acompanhada por altera&#231;&#245;es morfol&#243;gicas e ultraestruturais importantes, por&#233;m com altera&#231;&#245;es funcionais discretas nos cora&#231;&#245;es normais<sup>38-41</sup>. Por sua vez, no cora&#231;&#227;o hipertrofiado de ratos espontaneamente hipertensos, a restri&#231;&#227;o da ingest&#227;o alimentar induziu, al&#233;m de altera&#231;&#245;es morfol&#243;gicas, tamb&#233;m piora da fun&#231;&#227;o ventricular e mioc&#225;rdica<sup>42-45</sup>. Esses dados mostram que o desenvolvimento de caquexia pode levar a altera&#231;&#245;es card&#237;acas adicionais e agravamento do quadro preexistente de IC.</p>
    <p>Finalmente, na IC, a combina&#231;&#227;o de caquexia e ativa&#231;&#227;o imunol&#243;gica pode induzir anormalidades da musculatura esquel&#233;tica, com redu&#231;&#227;o da capacidade para realizar esfor&#231;os f&#237;sicos e piora da qualidade de vida. A inatividade f&#237;sica, por sua vez, resulta em perda de massa muscular e agravamento do quadro de caquexia<sup>9,12,16,46,47</sup>.</p>
    <p>
      <bold>Tratamento das altera&#231;&#245;es do TGI associadas a IC</bold>
    </p>
    <p>Abordaremos agora os poss&#237;veis alvos terap&#234;uticos para impedir ou reduzir altera&#231;&#245;es gastrointestinais associadas a IC e suas consequ&#234;ncias sist&#234;micas. Como as altera&#231;&#245;es do TGI induzem redu&#231;&#227;o da absor&#231;&#227;o intestinal de nutrientes, &#233; importante realizar terapia nutricional precocemente para, se poss&#237;vel, impedir o desenvolvimento de caquexia e, se necess&#225;rio, trat&#225;-la de forma agressiva. A terapia nutricional na IC &#233; complexa e n&#227;o faz parte dos objetivos desta revis&#227;o. </p>
    <p>Como previamente discutido, o edema de al&#231;as intestinais leva a altera&#231;&#227;o da permeabilidade intestinal e absor&#231;&#227;o de endotoxinas. Assim, &#233; importante manter os pacientes com o menor grau de edema poss&#237;vel. Al&#233;m da terapia diur&#233;tica, bloqueio neuro-hormonal deve ser realizado de acordo com as diretrizes atuais, visando &#224; melhora do quadro de IC. </p>
    <p>Defici&#234;ncia de ferro deve ser rotineiramente pesquisada e tratada com administra&#231;&#227;o de ferro por via oral ou intravenosa. Apesar de estudos experimentais terem mostrado redu&#231;&#227;o da transloca&#231;&#227;o intestinal com antibioticoterapia, ainda n&#227;o foi definido se modula&#231;&#227;o da microflora intestinal pode ser &#250;til no controle do processo inflamat&#243;rio sist&#234;mico. Portanto, descontamina&#231;&#227;o intestinal seletiva n&#227;o est&#225; indicada na IC<sup>9,12</sup>.</p>
    <p>Como existe dificuldade para se evitar a absor&#231;&#227;o inadequada de constituintes bacterianos, procurou-se bloquear seus efeitos sist&#234;micos. Na &#250;ltima d&#233;cada, foram realizados diversos estudos cl&#237;nicos avaliando os efeitos de v&#225;rios agentes imunomoduladores<sup>48</sup>. Entre os f&#225;rmacos com atividade anti-TNF-&#945;, destacam-se o etanercept e o infliximab. Em grandes estudos cl&#237;nicos, esses agentes tiveram resultados nulos ou pioraram a evolu&#231;&#227;o da IC, sendo, portanto, contraindicados atualmente<sup>49,50</sup>. Outro imunomodulador avaliado na IC foi a pentoxifilina. Entre suas poss&#237;veis a&#231;&#245;es est&#225; a inibi&#231;&#227;o da s&#237;ntese de citocinas, particularmente do TNF-&#945;. A pentoxifilina foi testada apenas em estudos pequenos, que tiveram resultados favor&#225;veis ou nulos<sup>51</sup>. Tamb&#233;m a talidomida, avaliada em pequenos estudos, apresentou resultados divergentes<sup>48</sup>. Finalmente, estudos preliminares com a administra&#231;&#227;o de imunoglobulina mostraram resultados positivos, como melhora na fra&#231;&#227;o de eje&#231;&#227;o<sup>48</sup>. Atualmente, entre as perspectivas para o futuro, diversos potenciais agentes imunomodulat&#243;rios encontram-se em investiga&#231;&#227;o experimental, como inibidores da ativa&#231;&#227;o de c&#233;lulas T, antagonistas de quimiocinas espec&#237;ficas, IL-10, antagonistas dos receptores da IL-1, inibi&#231;&#227;o da TACE, inibi&#231;&#227;o da p38 MAP Kinase, metotrexate e n-acetilciste&#237;na<sup>23,52</sup>. Finalmente, considera-se que exerc&#237;cios f&#237;sicos possam ter papel importante na modula&#231;&#227;o da resposta inflamat&#243;ria exacerbada na IC<sup>53,54</sup>. De fato, Adamopoulos e cols.<sup>55</sup> mostraram que o exerc&#237;cio f&#237;sico regular pode reduzir a concentra&#231;&#227;o s&#233;rica de TNF-&#945; e de IL-6. </p>
    <p>Em resumo, na insufici&#234;ncia card&#237;aca ocorrem altera&#231;&#245;es estruturais e funcionais do trato gastrointestinal. Suas consequ&#234;ncias cl&#237;nicas incluem piora do estado nutricional, ativa&#231;&#227;o inflamat&#243;ria sist&#234;mica e anemia. Essas condi&#231;&#245;es, isoladas ou em combina&#231;&#227;o, induzem altera&#231;&#245;es card&#237;acas e piora da disfun&#231;&#227;o ventricular preexistente. No momento, n&#227;o h&#225; modalidade terap&#234;utica definida para impedir ou reduzir altera&#231;&#245;es gastrointestinais associadas a insufici&#234;ncia card&#237;aca e suas consequ&#234;ncias sist&#234;micas.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="not" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Marina P. Okoshi </p>
        <p> Departamento de Cl&#237;nica M&#233;dica </p>
        <p> Rubi&#227;o Jr </p>
        <p> 18618-000 - Botucatu - SP, Brasil </p>
        <p> E-mail: </p>
        <p>
          <email xlink:href="mpoliti@fmb.unesp.br">mpoliti@fmb.unesp.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 27/06/11; revisado recebido em 27/06/11; aceito em 28/12/11.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Hess OM, Carroll JD. Clinical assessment of heart failure. In: Libby P, Bonow RO, Mann DL, Zipes DP, Braunwald E. (eds). Braunwald's heart disease: a textbook of cardiovascular medicine. 8<sup>th</sup> ed. Philadelphia: Saunders Elsevier; 2008. p. 561-81.</mixed-citation>
        <element-citation publication-type="book">
          <source>Braunwald's heart disease: a textbook of cardiovascular medicine</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>561</fpage>
          <lpage>81</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Hess</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Carroll</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Libby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Zipes</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Braunwald</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Sim&#245;es MV, Rossi Neto JM. A insufici&#234;ncia card&#237;aca no Brasil e no mundo. In: Serrano Jr CV, Timerman A, Stefanini E. (eds). Tratado de cardiologia. SOCESP. 2&#350; ed. S&#227;o Paulo: Manole; 2009. p. 1019-28.</mixed-citation>
        <element-citation publication-type="book">
          <source>Tratado de cardiologia: SOCESP</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1019</fpage>
          <lpage>28</lpage>
          <person-group person-group-type="author">
            <name>
              <surname>Sim&#245;es</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Rossi Neto</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Serrano Jr</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Timerman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Stefanini</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Davidson JD, Waldmann TA, Goodman DS, Gordon RS Jr. Protein-losing gastroenteropathy in congestive heart-failure. Lancet. 1961;1(7183):899-902.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Protein-losing gastroenteropathy in congestive heart-failure</article-title>
          <source>Lancet</source>
          <date>
            <year>1961</year>
          </date>
          <fpage>899</fpage>
          <lpage>902</lpage>
          <issue>7183</issue>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Davidson</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Waldmann</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Goodman</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Gordon Jr</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Raja K, Kochhar R, Sethy PK, Dutta U, Bali HK, Varma JS. An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure. Gastrointest Endosc. 2004;60(6):887-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure</article-title>
          <source>Gastrointest Endosc</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>887</fpage>
          <lpage>93</lpage>
          <issue>6</issue>
          <volume>60</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Raja</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kochhar</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Sethy</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Dutta</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Bali</surname>
              <given-names>HK</given-names>
            </name>
            <name>
              <surname>Varma</surname>
              <given-names>JS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Sandek A, Anker SD, von Haehling S. The gut and intestinal bacteria in chronic heart failure. Curr Drug Metab. 2009;10(1):22-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The gut and intestinal bacteria in chronic heart failure</article-title>
          <source>Curr Drug Metab</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>22</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sandek</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>von Haehling</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50(16):1561-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Altered intestinal function in patients with chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>1561</fpage>
          <lpage>9</lpage>
          <issue>16</issue>
          <volume>50</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sandek</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bauditz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Swidsinski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Buhner</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Weber-Eibel</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>von Haehling</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Arutyunov GP, Kostyukevich OI, Serov RA, Rylova NV, Bylova NA. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol. 2008;125(2):240-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>240</fpage>
          <lpage>5</lpage>
          <issue>2</issue>
          <volume>125</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Arutyunov</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Kostyukevich</surname>
              <given-names>OI</given-names>
            </name>
            <name>
              <surname>Serov</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Rylova</surname>
              <given-names>NV</given-names>
            </name>
            <name>
              <surname>Bylova</surname>
              <given-names>NA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Ralevic V. Splanchnic circulatory physiology. Hepatogastroenterology. 1999;46(Suppl 2):1409-13.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Splanchnic circulatory physiology</article-title>
          <source>Hepatogastroenterology</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1409</fpage>
          <lpage>13</lpage>
          <volume>46</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ralevic</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005;26(22):2368-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The importance of the gastrointestinal system in the pathogenesis of heart failure</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2368</fpage>
          <lpage>74</lpage>
          <issue>22</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Krack</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Figulla</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Krack A, Richartz BM, Gastmann A, Greim K, Lotze U, Anker SD, et al. Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure. Eur J Heart Fail. 2004;6(4):403-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Studies on intragastric PCO2 at rest and during exercise as a marker of intestinal perfusion in patients with chronic heart failure</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>403</fpage>
          <lpage>7</lpage>
          <issue>4</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Krack</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Richartz</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Gastmann</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Greim</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Lotze</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. King D, Smith ML, Chapman TJ, Stockdale HR, Lye M. Fat malabsorption in elderly patients with cardiac cachexia. Age Ageing. 1996;25(2):144-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Fat malabsorption in elderly patients with cardiac cachexia</article-title>
          <source>Age Ageing</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>144</fpage>
          <lpage>9</lpage>
          <issue>2</issue>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Stockdale</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Lye</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD. Inflammatory biomarkers in heart faiulre revisited: much more than innocent bystanders. Heart Fail Clin. 2009;5(4):549-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Inflammatory biomarkers in heart faiulre revisited: much more than innocent bystanders</article-title>
          <source>Heart Fail Clin</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>549</fpage>
          <lpage>60</lpage>
          <issue>4</issue>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>von Haehling</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schefold</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Lainscak</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Doehner</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353(9167):1838-42.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Endotoxin and immune activation in chronic heart failure: a prospective cohort study</article-title>
          <source>Lancet</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1838</fpage>
          <lpage>42</lpage>
          <issue>9167</issue>
          <volume>353</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Niebauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Volk</surname>
              <given-names>HD</given-names>
            </name>
            <name>
              <surname>Kemp</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dominguez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schumann</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Rauchhaus</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Elevated circulating levels of tumor necrosis factor in severe chronic heart failure</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>236</fpage>
          <lpage>41</lpage>
          <issue>4</issue>
          <volume>323</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levine</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kalman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mayer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Fillit</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Packer</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Dunlay SM, Weston SA, Redfield MM, Killian JM, Roger VL. Tumor necrosis factor-alpha and mortality in heart failure: a community study. Circulation. 2008;118(6):625-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tumor necrosis factor-alpha and mortality in heart failure: a community study</article-title>
          <source>Circulation</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>625</fpage>
          <lpage>31</lpage>
          <issue>6</issue>
          <volume>118</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dunlay</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Weston</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Redfield</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Killian</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Roger</surname>
              <given-names>VL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Martinez PF, Okoshi K, Zornoff LA, Carvalho RF, Oliveira Junior SA, Lima AR, et al. Chronic heart failure-induced skeletal muscle atrophy, necrosis, and myogenic regulatory factors changes. Med Sci Monit. 2010;16(12):BR374-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chronic heart failure-induced skeletal muscle atrophy, necrosis, and myogenic regulatory factors changes</article-title>
          <source>Med Sci Monit</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>BR374</fpage>
          <lpage>83</lpage>
          <issue>12</issue>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Martinez</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Zornoff</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Oliveira Junior</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>AR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92(6):1479-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1479</fpage>
          <lpage>86</lpage>
          <issue>6</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferrari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Bachetti</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Confortini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Opasich</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Febo</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Corti</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation. 2000;102(25):3060-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Plasma cytokine parameters and mortality in patients with chronic heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>3060</fpage>
          <lpage>7</lpage>
          <issue>25</issue>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rauchhaus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Doehner</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Francis</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Davos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kemp</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liebenthal</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103(16):2055-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST)</article-title>
          <source>Circulation</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2055</fpage>
          <lpage>9</lpage>
          <issue>16</issue>
          <volume>103</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Deswal</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Petersen</surname>
              <given-names>NJ</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>White</surname>
              <given-names>BG</given-names>
            </name>
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Vaz Perez A, Doehner W, von Haehling S, Schmidt H, Zimmermann AV, Volk HD, et al. The relationship between tumor necrosis factor-a, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 2010;141(1):39-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The relationship between tumor necrosis factor-a, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>39</fpage>
          <lpage>43</lpage>
          <issue>1</issue>
          <volume>141</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vaz Perez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Doehner</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>von Haehling</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Schmidt</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Volk</surname>
              <given-names>HD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Bozkurt B, Kribbs SB, Clubb FJ Jr, Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97(14):1382-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats</article-title>
          <source>Circulation</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1382</fpage>
          <lpage>91</lpage>
          <issue>14</issue>
          <volume>97</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bozkurt</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kribbs</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>Clubb Jr</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Michael</surname>
              <given-names>LH</given-names>
            </name>
            <name>
              <surname>Didenko</surname>
              <given-names>VV</given-names>
            </name>
            <name>
              <surname>Hornsby</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Sivasubramanian N, Coker ML, Kurrelmeyer KM, MacLellan WR, DeMayo FJ, Spinale FG, et al. Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2001;104(7):826-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular remodeling in transgenic mice with cardiac restricted overexpression of tumor necrosis factor</article-title>
          <source>Circulation</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>826</fpage>
          <lpage>31</lpage>
          <issue>7</issue>
          <volume>104</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sivasubramanian</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Coker</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Kurrelmeyer</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>MacLellan</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>DeMayo</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Spinale</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P. Systemic inflammation in heart failure - the whys and wherefores. Heart Fail Rev. 2006;11(1):83-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Systemic inflammation in heart failure: the whys and wherefores</article-title>
          <source>Heart Fail Rev</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>83</fpage>
          <lpage>92</lpage>
          <issue>1</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yndestad</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Damas</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Oie</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Ueland</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gullestad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Aukrust</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Sorkine P, Szold O, Halpern P, Gutman M, Greemland M, Rudick V, et al. Gut decontamination reduces bowel ischemia-induced lung injury in rats. Chest. 1997;112(2):491-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Gut decontamination reduces bowel ischemia-induced lung injury in rats</article-title>
          <source>Chest</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>491</fpage>
          <lpage>5</lpage>
          <issue>2</issue>
          <volume>112</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sorkine</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Szold</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Halpern</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Gutman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Greemland</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rudick</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Rauchhaus M, Clark AL, Doehner W, Davos C, Bolger A, Sharma R, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003;42(11):1933-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The relationship between cholesterol and survival in patients with chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1933</fpage>
          <lpage>40</lpage>
          <issue>11</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rauchhaus</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Doehner</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Davos</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bolger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8(4):216-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>216</fpage>
          <lpage>24</lpage>
          <issue>4</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Horwich</surname>
              <given-names>TB</given-names>
            </name>
            <name>
              <surname>Hamilton</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Maclellan</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Fonarow</surname>
              <given-names>GC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008;52(10):818-27.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia and mortality in heart failure patients a systematic review and meta-analysis</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>818</fpage>
          <lpage>27</lpage>
          <issue>10</issue>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Groenveld</surname>
              <given-names>HF</given-names>
            </name>
            <name>
              <surname>Januzzi</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Damman</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>van Wijngaarden</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hillege</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>van Veldhuisen</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Ghali JK. Anemia and heart failure. Curr Opin Cardiol. 2009;24:172-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia and heart failure</article-title>
          <source>Curr Opin Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>172</fpage>
          <lpage>8</lpage>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ghali</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia of chronic disease</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1011</fpage>
          <lpage>23</lpage>
          <issue>10</issue>
          <volume>352</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Weiss</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Goodnough</surname>
              <given-names>LT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome C release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond). 2005;109(3):277-86.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome C release: involvement of nitric oxide synthase and protein tyrosine nitration</article-title>
          <source>Clin Sci (Lond)</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>277</fpage>
          <lpage>86</lpage>
          <issue>3</issue>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Culver</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chew Jr</surname>
              <given-names>HG</given-names>
            </name>
            <name>
              <surname>Kelley</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Ren</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Jankowska EA, Ponikowski P. Molecular changes in myocardium in the course of anemia or iron deficiency. Heart Fail Clin. 2010;6(3):295-304.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Molecular changes in myocardium in the course of anemia or iron deficiency</article-title>
          <source>Heart Fail Clin</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>295</fpage>
          <lpage>304</lpage>
          <issue>3</issue>
          <volume>6</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jankowska</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Ponikowski</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Bolger AP, Bartlett FR, Penston HS, O'Leary J, Pollock N, Kaprielian R, et al. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. J Am Coll Cardiol. 2006;48(6):1225-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Intravenous iron alone for the treatment of anemia in patients with chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1225</fpage>
          <lpage>7</lpage>
          <issue>6</issue>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bolger</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Bartlett</surname>
              <given-names>FR</given-names>
            </name>
            <name>
              <surname>Penston</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>O'Leary</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pollock</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Kaprielian</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Opasich C, Cazzola M, Scelsi L, De Feo S, Bosimini E, Lagioia R, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J. 2005;26(21):2232-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>2232</fpage>
          <lpage>7</lpage>
          <issue>21</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Opasich</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cazzola</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Scelsi</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>De Feo</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bosimini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lagioia</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Nanas JN, Matsouka C, Karageorgopoulos D, Leonti A, Tsolakis E, Drakos SG, et al. Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol. 2006;48(12):2485-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Etiology of anemia in patients with advanced heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2485</fpage>
          <lpage>9</lpage>
          <issue>12</issue>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nanas</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Matsouka</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Karageorgopoulos</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Leonti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tsolakis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Drakos</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LA, Skali H, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2007;116(6):627-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Body mass index and prognosis in patients with chronic heart failure: insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>627</fpage>
          <lpage>36</lpage>
          <issue>6</issue>
          <volume>116</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kenchaiah</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pocock</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Finn</surname>
              <given-names>PV</given-names>
            </name>
            <name>
              <surname>Zornoff</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Skali</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361(9363):1077-83.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study</article-title>
          <source>Lancet</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1077</fpage>
          <lpage>83</lpage>
          <issue>9363</issue>
          <volume>361</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Anker</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Negassa</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Afzal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Poole-Wilson</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Cohn</surname>
              <given-names>JN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Okoshi MP, Campana AO, Okoshi K, Paiva SAR, Cicogna AC. Caquexia em insufici&#234;ncia card&#237;aca. Rev Bras Med. 2001;58(10):742-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Caquexia em insufici&#234;ncia card&#237;aca</article-title>
          <source>Rev Bras Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>742</fpage>
          <lpage>9</lpage>
          <issue>10</issue>
          <volume>58</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Campana</surname>
              <given-names>AO</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Paiva</surname>
              <given-names>SAR</given-names>
            </name>
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Cicogna AC, Padovani CR, Okoshi K, Matsubara LS, Aragon FF, Okoshi MP. The influence of temporal food restriction on the performance of isolated cardiac muscle. Nutr Res. 2001;21(4):639-48.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The influence of temporal food restriction on the performance of isolated cardiac muscle</article-title>
          <source>Nutr Res</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>639</fpage>
          <lpage>48</lpage>
          <issue>4</issue>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Padovani</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Aragon</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Fioretto JR, Querioz SS, Padovani CR, Matsubara LS, Okoshi K, Matsubara BB. Ventricular remodeling and diastolic myocardial dysfunction in rats submitted to protein-calorie malnutrition. Am J Physiol Heart Circ Physiol. 2002;282(4):H1327-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Ventricular remodeling and diastolic myocardial dysfunction in rats submitted to protein-calorie malnutrition</article-title>
          <source>Am J Physiol Heart Circ Physiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>H1327</fpage>
          <lpage>33</lpage>
          <issue>4</issue>
          <volume>282</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fioretto</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Querioz</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Padovani</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>BB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Okoshi MP, Okoshi K, Pai VD, Pai-Silva MD, Matsubara LS, Cicogna AC. Mechanical, biochemical, and morphological changes in the heart from chronic food restricted rats. Can J Physiol Pharmacol. 2001;79(9):754-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mechanical, biochemical, and morphological changes in the heart from chronic food restricted rats</article-title>
          <source>Can J Physiol Pharmacol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>754</fpage>
          <lpage>60</lpage>
          <issue>9</issue>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pai</surname>
              <given-names>VD</given-names>
            </name>
            <name>
              <surname>Pai-Silva</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Gut AL, Okoshi MP, Padovani CR, Aragon FF, Cicogna AC. Myocardial dysfunction induced by food restriction is related to calcium cycling and beta-adrenergic system changes. Nutr Res. 2003;23(7):911-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial dysfunction induced by food restriction is related to calcium cycling and beta-adrenergic system changes</article-title>
          <source>Nutr Res</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>911</fpage>
          <lpage>9</lpage>
          <issue>7</issue>
          <volume>23</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gut</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Padovani</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Aragon</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Gut AL, Sugizaki MM, Okoshi MP, Carvalho RF, Pai-Silva MD, Aragon FF, et al. Food restriction impairs myocardial inotropic response to calcium and beta-adrenergic stimulation in spontaneously hypertensive rats. Nutr Res. 2008;28(10):722-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Food restriction impairs myocardial inotropic response to calcium and beta-adrenergic stimulation in spontaneously hypertensive rats</article-title>
          <source>Nutr Res</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>722</fpage>
          <lpage>7</lpage>
          <issue>10</issue>
          <volume>28</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gut</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Sugizaki</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Pai-Silva</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Aragon</surname>
              <given-names>FF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Cicogna AC, Padovani CR, Georgette JC, Aragon FF, Okoshi MP. Efeito da restri&#231;&#227;o prot&#233;ico-cal&#243;rica sobre a fun&#231;&#227;o mec&#226;nica dos m&#250;sculos card&#237;acos hipertrofiados. Arq Bras Cardiol. 1999;72(4):431-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Efeito da restri&#231;&#227;o prot&#233;ico-cal&#243;rica sobre a fun&#231;&#227;o mec&#226;nica dos m&#250;sculos card&#237;acos hipertrofiados</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>431</fpage>
          <lpage>5</lpage>
          <issue>4</issue>
          <volume>72</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Padovani</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Georgette</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Aragon</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Okoshi MP, Okoshi K, Matsubara LS, Dal Pai-Silva M, Gut AL, Padovani CR, et al. Myocardial remodeling and dysfunction are induced by chronic food restriction in spontaneously hypertensive rats. Nutr Res. 2006;26(11):567-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial remodeling and dysfunction are induced by chronic food restriction in spontaneously hypertensive rats</article-title>
          <source>Nutr Res</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>567</fpage>
          <lpage>72</lpage>
          <issue>11</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matsubara</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Dal Pai-Silva</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gut</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Padovani</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. Sugizaki MM, Carvalho RF, Aragon FF, Padovani CR, Okoshi K, Okoshi MP, et al. Myocardial dysfunction induced by food restriction is related to morphological damage in normotensive middle-aged rats. J Biomed Sci. 2005;12(4):641-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial dysfunction induced by food restriction is related to morphological damage in normotensive middle-aged rats</article-title>
          <source>J Biomed Sci</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>641</fpage>
          <lpage>9</lpage>
          <issue>4</issue>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sugizaki</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Aragon</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Padovani</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Lima AR, Martinez PF, Okoshi K, Guizoni DM, Zornoff LA, Campos DH, et al. Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure. Int J Exp Path. 2010;91(1):54-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myostatin and follistatin expression in skeletal muscles of rats with chronic heart failure</article-title>
          <source>Int J Exp Path</source>
          <date>
            <year>2010</year>
          </date>
          <fpage>54</fpage>
          <lpage>62</lpage>
          <issue>1</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lima</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Martinez</surname>
              <given-names>PF</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Guizoni</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Zornoff</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Carvalho RF, Cicogna AC, Campos GE, De Assis JM, Padovani CR, Okoshi MP, et al. Myosin heavy chain expression and atrophy in rat skeletal muscle during transition from cardiac hypertrophy to heart failure. Int J Exp Path. 2003;84(4):201-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myosin heavy chain expression and atrophy in rat skeletal muscle during transition from cardiac hypertrophy to heart failure</article-title>
          <source>Int J Exp Path</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>201</fpage>
          <lpage>6</lpage>
          <issue>4</issue>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Carvalho</surname>
              <given-names>RF</given-names>
            </name>
            <name>
              <surname>Cicogna</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>De Assis</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Padovani</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Okoshi</surname>
              <given-names>MP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Fildes JE, Shaw SM, Yonan N, Williams SG. The immune system and chronic heart failure: is the heart in control? J Am Coll Cardiol. 2009;53(12):1013-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The immune system and chronic heart failure: is the heart in control?</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1013</fpage>
          <lpage>20</lpage>
          <issue>12</issue>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Fildes</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Yonan</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107(25):3133-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>3133</fpage>
          <lpage>40</lpage>
          <issue>25</issue>
          <volume>107</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chung</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Packer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lo</surname>
              <given-names>KH</given-names>
            </name>
            <name>
              <surname>Fasanmade</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Willerson</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B50">
        <mixed-citation>50. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109(13):1594-602.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1594</fpage>
          <lpage>602</lpage>
          <issue>13</issue>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mann</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>McMurray</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Packer</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Swedberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Borer</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Colucci</surname>
              <given-names>WS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B51">
        <mixed-citation>51. Shaw SM, Shah MK, Williams SG, Fildes JE. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail. 2009;11(2):113-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Immunological mechanisms of pentoxifylline in chronic heart failure</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>113</fpage>
          <lpage>8</lpage>
          <issue>2</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shaw</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Fildes</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B52">
        <mixed-citation>52. Bourraindeloup M, Adamy C, Candiani G, Cailleret M, Bourin MC, Badoual T, et al. N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats. Circulation. 2004;110(14):2003-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>N-acetylcysteine treatment normalizes serum tumor necrosis factor-alpha level and hinders the progression of cardiac injury in hypertensive rats</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2003</fpage>
          <lpage>9</lpage>
          <issue>14</issue>
          <volume>110</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bourraindeloup</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Adamy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Candiani</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cailleret</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bourin</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Badoual</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B53">
        <mixed-citation>53. Kinugawa T, Kato M, Ogino K, Osaki S, Tomikura Y, Igawa O, et al. Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure. Int J Cardiol. 2003;87(1):83-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>83</fpage>
          <lpage>90</lpage>
          <issue>1</issue>
          <volume>87</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kinugawa</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kato</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ogino</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Osaki</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tomikura</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Igawa</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B54">
        <mixed-citation>54. Niebauer J, Clark AL, Webb-Peploe KM, Coats AJ. Exercise training in chronic heart failure: effects of pro-inflammatory markers. Eur J Heart Fail. 2005;7(2):189-93.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise training in chronic heart failure: effects of pro-inflammatory markers</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>189</fpage>
          <lpage>93</lpage>
          <issue>2</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Niebauer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Webb-Peploe</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B55">
        <mixed-citation>55. Adamopoulos S, Parissis J, Karatzas D, Kroupis C, Georgiadis M, Karavolias G, et al. Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure. J Am Coll Cardiol. 2002;39(4):653-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fas ligand system in patients with chronic heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>653</fpage>
          <lpage>63</lpage>
          <issue>4</issue>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Adamopoulos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Parissis</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Karatzas</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kroupis</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Georgiadis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Karavolias</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Gastrointestinal changes associated to heart failure</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Over the last decade, several studies were conducted on the gastrointestinal changes associated to chronic heart failure. This article presents a literature review on the physiopathology and clinical consequences of pathological digestive changes of heart failure patients. Structural and functional abnormalities of the gastrointestinal tract, such as edema of absorptive mucosa and intestinal bacterial overgrowth, have been leading to serious clinical consequences. Some of these consequences are cardiac cachexia, systemic inflammatory activation and anemia. These conditions, alone or in combination, may lead to worsening of the pre-existing ventricular dysfunction. Although currently there is no therapy specifically earmarked for gastrointestinal changes associated to heart failure, the understanding of digestive abnormalities is germane for the prevention and management of systemic consequences.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Heart failure</kwd>
        <kwd>cachexia</kwd>
        <kwd>abnormalities of the digestive system</kwd>
        <kwd>intestinal absorption</kwd>
        <kwd>anemia</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>REVIEW ARTICLE</bold>
      </p>
      <p>
        <fn id="nota-body2">
          <label>
            <bold>Gastrointestinal changes associated to heart failure</bold>
          </label>
          <p>
            <bold>Fernando G. Romeiro; Katashi Okoshi; Leonardo A. M. Zornoff; Marina P. Okoshi</bold>
          </p>
        </fn>
      </p>
      <p>Faculdade de Medicina de Botucatu, SP, Brazil</p>
      <p>Mailing Address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>Over the last decade, several studies were conducted on the gastrointestinal changes associated to chronic heart failure. This article presents a literature review on the physiopathology and clinical consequences of pathological digestive changes of heart failure patients. Structural and functional abnormalities of the gastrointestinal tract, such as edema of absorptive mucosa and intestinal bacterial overgrowth, have been leading to serious clinical consequences. Some of these consequences are cardiac cachexia, systemic inflammatory activation and anemia. These conditions, alone or in combination, may lead to worsening of the pre-existing ventricular dysfunction. Although currently there is no therapy specifically earmarked for gastrointestinal changes associated to heart failure, the understanding of digestive abnormalities is germane for the prevention and management of systemic consequences.</p>
      <p><bold>Keywords:</bold> Heart failure/complications, cachexia, abnormalities of the digestive system, intestinal absorption, anemia</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart Failure (HF) may be defined as a complex clinical syndrome that comes from structural and/or functional, acquired or hereditary cardiac abnormalities, and lead to the worsening of the filling capacity and ventricular ejection<sup>1</sup>. It stands as a clinical problem of utmost importance, both due to its high prevalence, and the severity of its clinical manifestations. In Brazil, this is the third cause of hospitalization and the first cause of hospital admission due to cardiovascular disease. According to data of Datasus, in 2003, there were more than 350,000 hospital admissions due to HF countrywide<sup>2</sup>.</p>
      <p>The most common causes of HF are myocardial ischemia, hypertension, cardiomyopathies and valvopathy. In many cases, however, the etiology is still unknown.</p>
      <p>The pioneering studies by Frank, in 1895, and Starling, in 1918, introduced the concept that changes in the heart's relaxation and ejection function are responsible for the development and progression of HF. Nonetheless, over the last decades, the fact that the HF is a much more complex syndrome has been established and, thus, the cardiovascular system is no longer seen as the only to be impacted, but the renal, neuroendocrine, immunological, musculoskeletal, hematologic and gastrointestinal systems as well. Because of this, researches have been performed to elucidate the physiopathology of systemic complications and to propose a treatment capable of improving life quality and expectancy of patients suffering from the disease. They include, <italic>inter alia,</italic> studies about the impairment of the Gastrointestinal Tract (GIT) in HF.</p>
      <p>In this review, we will show the structural and functional changes which may occur in the GIT of patients with HF. Subsequently, we will present the manifestations arising out of the GIT impairment, mainly the inappropriate absorption of bacterial constituents. Lastly, we will address the current strategies and those under research to prevent and/or treat GIT changes associated to HF and its systemic consequences.</p>
      <p>The GIT impairment in HF has been firstly studied in 1960 by Davidson et al<sup>3</sup> The authors showed that patients undergoing constrictive pericarditis presented protein-losing gastroenteropathy, reversible after surgical correction of cardiac lesion. In spite of the initial studies, only over the last decade the GIT has been more thoroughly evaluated in HF.</p>
      <p>
        <bold>Structural gastrointestinal changes associated to HF</bold>
      </p>
      <p>Several structural changes have been described in the GIT of patients with HF. Several abnormalities of the gastric mucosa in mosaic pattern were observed in the stomach, including the antral vascular ectasia, mucosal thickening and areas of telangiectasias<sup>4,5</sup>.</p>
      <p>In the terminal ileum, colon and sigmoid, ultrasound resonance has found increase in the intestinal wall thickness, suggesting the presence of edema of the loops in patients with HF<sup>6</sup>. Although the belief in the existence of intestinal wall edema in patients with important water retention has long existed, this was the first report of change substantiated by imaging examination performed <italic>in vivo</italic>. The sigmoid wall thickness seems to present clinical implications, as their measurements have always been positively related to the blood concentration of leukocytes and ultra-sensitive C-reactive Protein (CRP)<sup>6</sup>. These results suggest that intestinal changes have relevance in the induction of systemic influence, as we will see subsequently. The small intestine wall presents both thickening and increase of the collagen tissue, which is proportional to the severity of HF<sup>7</sup>. To this respect, the distance between the enterocyte basal membrane and the blood capillary is increased<sup>7</sup>, possibly due to the said changes 7. Currently, these structural changes are believed to worsen the nutrition of enterocytes and, consequently, to lead to abnormalities in the intestinal Absorption associated to the HF.</p>
      <p>
        <bold>Functional gastrointestinal changes associated to HF</bold>
      </p>
      <p>In physiological conditions, the splanchnic circulation received nearly 25% of the cardiac output, leading the intestine to be one of the organs more intensely perfused in rest<sup>8</sup>. The splanchnic circulation is richly supplied with sympathetic nerves. Consequently, the increase in the sympathetic nervous system activities triggers the constriction of pre-capillary resistance vessels and post-capillary capacitance vessels, entailing reduction of blood perfusion. The intestinal vascular changes may precede changes in heart rate or blood pressure<sup>9</sup>. On account of this, even discrete reductions of the cardiac output may lead to different degrees of intestinal ischemia. In patients with advanced HF, Krack et al<sup>10</sup> observed intramucosal acidosis in the stomach induced by light physical activity, evidencing, however, the occurrence of hypoperfusion of GIT. </p>
      <p>The functional changes involve abnormalities of intestinal permeability. The Intestinal Absorption happens through transcellular routes, in which the food constituents are absorbed to the interior of the enterocyte and, subsequently, to the blood capillary and, through paracellular route, in which they are passively absorbed while passing between enterocytes<sup>5</sup>. The paracellular absorption route may be evaluated by sugar administration tests and subsequent analyses of its concentration in urine<sup>6</sup>. Both in the small intestine and in colons, the independent paracellular absorption of transfer proteins is increased in HF, suggesting rupture of the intestinal barrier<sup>5,6</sup>. In its turn, the passive transfer mediated by transfer proteins of the small intestine is reduced in HF, suggesting deficit of ATP for microcirculation<sup>6</sup>.</p>
      <p>In 1996, King et al<sup>11</sup> observed that patients with HF and cachexia presented reduction of the intestinal absorption of fats compared to patients who did not undergo cachexia or healthy individuals. The decrease of intestinal absorption was well documented in a recent work, in which the higher loss of proteins and fats was found in the feces of patients with HF in functional classes III and IV than in those in classes I and II<sup>7</sup>. Additionally, the reduction of intestinal absorption was more evident in patients with cardiac cachexia. This, evidence suggest that changes in intestinal absorption may be involved in the etiology of cachexia associated to HF<sup>12</sup>.</p>
      <p>In addition to the changes in absorption, patients with HF present high level of intestinal bacterial colonization. Adopting the FISH (Fluorescence In Situ Hybridization) technique, one could evidence that the bacterial concentration in mucosal biofilm and the extent of bacterial adhesion to the sigmoid wall are increased in the HF<sup>6</sup>. Currently, the increase of intestinal bacterial colonization is believed to be the result of GIT structural and functional changes, probably jointly with immunological abnormalities associated to HF. </p>
      <p>One of the main consequences of gastrointestinal changes is the inappropriate absorption of bacterial constituents, especially endotoxins, also known as lipopolysaccharides<sup>5</sup>. Endotoxins are important toxic and immune components of Gram-negative bacteria. In spite of the difficulties for dosing endotoxins, Niebauer et al<sup>13</sup> showed that patients with HF and edema present increase in the plasma concentration of endoxins compared to those without edema. Additionally, after therapy with diuretics, there was normalization of the serum concentration of endotoxins<sup>13</sup>. This study was important to underscore the current hypothesis that the intestinal wall edema would be involved in the change of intestinal permeability and inappropriate absorptions of bacterial constituents. The intestinal edema and its systemic consequences seem to characterize the main difference, relating to GIT impairment, between chronic and stable HF and the decompensated HF. </p>
      <p>Currently, the lipopolysaccharides are considered one of the most powerful inducers of the tumor necrosis factor (TNF)-&#945; and other pro-inflammatory substances.</p>
      <p>The importance of TNF-&#945; in HF was primarily described by Levine et al<sup>14</sup> in 1990. The authors observed that patients with HF presented high serum levels of TNF-&#945; especially higher in those with cachexia. The findings were capital for the understanding of the HF physiopathology and its complications and have influenced the performance of a significant amount of research in this area<sup>15,16</sup>. Soon, the assumption that TNF-&#945; is a good marker of severity in HF has been substantiated, and correlating to the survival, the HF functional class, the cardiac performance and the serum concentration of brain natriuretic peptides<sup>17-20</sup>. In experimental studies, the increase of TNF-&#945;, induced by exogenous administration or by the increase of gene expression, leads to the HF phenotype, characterized by ventricular remodeling and reduction of survival<sup>21,22</sup>. These findings allowed to conclude that TNF-&#945; is not only a marker of severity, but also an inducer of HF and worsening of the ventricular dysfunction picture. Later on, researchers have found that, in addition to TNF-&#945;, other cytokines also increase in the HF.</p>
      <p>The sources producing cytokines are not yet fully clear. The very myocardium, if structurally damaged, may express and produce higher levels of inflammatory mediators, such as adhesion molecules, TNF-&#945; and IL-6. Circulating leukocytes, platelets, endothelial cells, and lung and liver cells may also be involved in the production of cytokines. To this respect, the inflammatory response does not depend on the HF etiology, happening as the common final pathway in patients with HF, irrespective of the cause of the disease<sup>23</sup>. The mechanisms proposed in the genesis of the production of cytokines include the hemodynamic overcharge, neuro-hormonal activation, presence of tissue hypoxemia and hypoperfusion, oxidation of low-density lipoprotein, presence of autoantibodies and immune stimulation caused by microbial agents, mainly the endotoxins<sup>23</sup>. </p>
      <p>Currently, one of the main stimuli for the cytokines in HF is believed to the absorption of endotoxins coming from the GIT<sup>23</sup>. The reduction of intracellular production of cytokines after selective intestinal decontamination with antibiotic underpins the assumption<sup>13,24</sup>. Endotoxins may be deactivated by serum cholesterol, which forms micellas in its surrounding, trapping them in its interior. This fact has been used to explain why patients with HF and high cholesterol have better survival than those with reduced cholesterol. According to the theory, higher serum concentrations of cholesterol imply higher neutralization of endotoxins<sup>25,26</sup>. More recently, the increase in the serum concentration of TNF-&#945; was observed to induce further changes in the intestinal epithelial barrier<sup>9,12</sup>. Thus, there is a vicious cycle in which the increase of serum concentration of a cytokine facilitates the absorption of endotoxins which, in their turn, induce the production of several cytokines.</p>
      <p>Therefore, we may conclude that the HF induces structural and functional abnormalities in GIT. One of the most important consequences of the GIT impairment is the change of intestinal absorption, leading to the impairment of the nutritional status and the immune activation<sup>9,12</sup>.</p>
      <p>
        <bold>Consequences of the gastrointestinal changes associated to HF</bold>
      </p>
      <p>
        <bold>Anemia</bold>
      </p>
      <p>In a recently published meta-analysis, including more than 153,000 patients with HF, the prevalence of anemia was 37.2%<sup>27</sup>. Several factors may be involved in the etiology of anemia, such as the decrease of the food intake, reduction of intestinal absorption, blood losses by GIT, abnormalities in the production of red blood cells, worsening of kidney function, chronic inflammation, blood dilution and the use of drugs<sup>28</sup>. Subsequently, we will briefly address the etiological factors involved in the genesis of anemia associated to HF which are the partial result of GIT abnormalities.</p>
      <p>The "needful" component seems to play an important role in the development of anemia. This would arise of the triad of changes commonly found in HF: reduction of food intake, decrease of intestinal absorption and blood losses by the GIT<sup>28</sup>. As in other chronic diseases, in HF there is activation of mechanisms involved in the reduction of the iron absorption. The lipopolysaccharides, such as the IL-6, induce the liver production of hepcidin, acute-phase protein which reduces the gastrointestinal iron absorption, leading to decrease in serum iron, a condition referred to as actual iron deficiency. Additionally, hepcidin reduces the release of iron in the stocks of macrophages and hepatocytes, also contributing to the reduction of serum iron, in this case referred to as iron functional deficiency<sup>29</sup>. Another factor which may induce anemia is the blood loss by GIT. Many patients with HF use antiplatelet agents, such as acetylsalicylic acid and/or anticoagulants. These drugs may both cause mucosa lesions in several parts of the GIT, and facilitate the blood loss by the digestive tube<sup>28</sup>.</p>
      <p>Iron deficiency, in addition to inhibiting erythropoiesis, may induce additional heart abnormalities, as it is associated with the activation of the sympathetic nervous system, ventricular dilatation, cardiac mitochondrial changes and thrombocytosis. The abnormalities associated to iron deficiency may be reversible with the iron administration. There are reports that the replacement of iron may even inhibit the production of TNF-&#945;<sup>30,31</sup>.</p>
      <p>Although it has not been systematically evaluated in large studies, iron deficiency was reported in 1% to 44% of the cases, depending on the severity of HF and the population studied<sup>32,33</sup>. In patients with severe HF, iron deficiency was the most frequent cause of anemia, accounting for 73% of the cases<sup>34</sup>. Nonetheless, many authors believe that, after correction of the iron deficiency, patients may develop the inflammatory component of the disease which causes anemia.</p>
      <p>
        <bold>Cachexia</bold>
      </p>
      <p>Other system consequence arising out at least partially of GIT changes and the immune activation during HF is cachexia. Currently, cachexia is considered a predictive factor of the reduced survival of patients with HF, irrespective of important variables, such as age, functional class of HF or ejection fraction<sup>35</sup>. </p>
      <p>Although the pathophysiology of cachexia associated to HF is not completely understood, several factors have been blamed for its development, such as decreased food intake, reduced intestinal absorption of nutrients, increased baseline energy expenditure and immune and neuroendocrine changes<sup>36,37</sup>.</p>
      <p>The cachexia is associated to several systemic complications, including the heart and skeletal muscle changes. Evaluating the impairment specifically of cachexia on o the heart is difficult, once it occurs in connection with the chronic inflammatory disease and, as already said, the immune activation leads to important deleterious effects in the heart<sup>12</sup>. In our laboratory, we evaluated the isolated effects of the restricted food intake on normotensive and hypertensive rats' hearts. The reduced body weight led to the diminishing of the cardiac muscle mass, which was followed by important morphological and ultrastructural changes, albeit with discrete functional changes in normal hearts<sup>38-41</sup>. In turn, in the hypertrophied heart of rats spontaneously hypertensive, the restricted food intake induced, in addition to morphological changes, the worsening of ventricular and myocardial function<sup>42-45</sup>. This data show that the development of cachexia may lead to additional heart changes and worsening of pre-existing HF picture.</p>
      <p>Lastly, in HF, the combination of cachexia and immune activation may induce abnormalities in skeletal muscles, entailing reduction of the capacity to perform physical efforts and the worsening of life quality. The physical inactivity, in its turn, results in loss of muscle mass and worsening of the cachexia picture<sup>9,12,16,46,47</sup>.</p>
      <p>
        <bold>Treatment of the GIT changes associated to HF</bold>
      </p>
      <p>We will now address the possible therapeutic targets to prevent or reduce gastrointestinal changes associated to HF and its systemic consequences. Insofar as the GIT changes induce reduction in intestinal absorption of nutrients, administering nutritional therapy early on is important, to prevent the development of cachexia and, if necessary, to treat it aggressively. The nutrition therapy in HF is complex and is not the object of our review. </p>
      <p>As discussed previously, the edema of the intestinal loops leads to change in intestinal permeability and absorption of endotoxins. Thus, maintaining patients with the possible lower edema level is important. In addition to the diuretic therapy, the neuro-hormonal blockade should be performed according to the current guidelines, aiming to improve the HF picture. </p>
      <p>The iron deficiency should be routinely tested and treated with the iron administration orally or intravenously. In spite of the experimental studies which have been showing reduction of intestinal shift with antibiotic therapy, there is no definition about the fact that modulation of intestinal microflora is useful to control the systemic inflammatory process. On account of this, the selective intestinal decontamination is not indicated for HF<sup>9,12</sup>.</p>
      <p>As there is difficulty preventing inappropriate absorption of bacterial constituents, their systemic effects may be blocked. Over the last decade, several clinical trials have been evaluating the effects of several immunomodulator agents<sup>48</sup>. The drugs with anti-TNF-&#945; activity include the etanercept and the infliximab. In large clinical trials, these agents have insignificant results or worsened the evolution of HF, and are currently contraindicated<sup>49,50</sup>. Another immunomodulator evaluated in HF was pentoxifylline. Its possible actions include the inhibition of the synthesis of cytokines, mainly the TNF-&#945;. Pentoxifylline was testes only in small studies, which had favorable or insignificant results<sup>51</sup>. Thalidomide, evaluated in small studies, presented divergent results<sup>48</sup>. Finally, preliminary studies with the administration of immunoglobulin showed positive results, such as the improvement in ejection fraction<sup>48</sup>. Currently, several potential immunomodulatory agents are under experimental investigation, such as inhibitors of T cells activation, antagonists of specific chemokines, IL-10, antagonists of IL-1 receptors, TACE inhibition, inhibition of p38 MAP kinase, methotrexate and n-acetylcysteine<sup>23,52</sup>. Lastly, physical exercises are believed to play an important role in the modulation of the increased inflammatory response in HF<sup>53,54</sup>. As a matter of fact, Adamopoulos et al<sup>55</sup> showed that regular physical exercises may reduce the serum concentration of TNF-&#945; and IL-6. </p>
      <p>In sum, there are structural and functional changes of the gastrointestinal tract in heart failure. Its clinical consequences include worsening of the nutritional status, systemic inflammatory activation and anemia. These conditions, either isolated or in combination, induce heart changes and worsening of pre-existing ventricular dysfunction. As for now, there is no definite therapeutic modality for preventing or reducing gastrointestinal changes associated to heart failure and its systemic consequences.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Alteraciones gastrointestinales asociadas a la insuficiencia card&#237;aca</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>En la &#250;ltima d&#233;cada, fueron realizados varios estudios sobre las alteraciones gastrointestinales asociadas a la Insuficiencia Card&#237;aca Cr&#243;nica. En este art&#237;culo, presentamos una revisi&#243;n de la literatura sobre la fisiopatolog&#237;a y las consecuencias cl&#237;nicas de las alteraciones patol&#243;gicas digestivas de pacientes con insuficiencia card&#237;aca. Las anormalidades estructurales y funcionales del tracto gastrointestinal, como el edema de la mucosa absortiva y el hipercrecimiento bacteriano intestinal, han sido responsabilizadas de las graves consecuencias cl&#237;nicas. Entre ellas destacamos la caquexia card&#237;aca, la activaci&#243;n inflamatoria sist&#233;mica y la anemia. Esas condiciones, aisladamente o de forma combinada, pueden conllevar al empeoramiento de la disfunci&#243;n ventricular preexistente. Aunque actualmente no exista una terap&#233;utica espec&#237;fica dirigida a las alteraciones gastrointestinales asociadas a la insuficiencia card&#237;aca, el entendimiento de las anormalidades digestivas es fundamental para su prevenci&#243;n y para el manejo de las consecuencias sist&#233;micas.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Insuficiencia card&#237;aca</kwd>
        <kwd>caquexia</kwd>
        <kwd>anormalidades del sistema digestivo</kwd>
        <kwd>absorci&#243;n intestinal</kwd>
        <kwd>anemia</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO DE REVISI&#211;N</bold>
      </p>
      <p>
        <fn id="inicio-body3">
          <label>
            <bold>Alteraciones gastrointestinales asociadas a la insuficiencia card&#237;aca</bold>
          </label>
          <p>
            <bold>Fernando G. Romeiro; Katashi Okoshi; Leonardo A. M. Zornoff; Marina P. Okoshi</bold>
          </p>
        </fn>
      </p>
      <p>Faculdade de Medicina de Botucatu, SP, Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>En la &#250;ltima d&#233;cada, fueron realizados varios estudios sobre las alteraciones gastrointestinales asociadas a la Insuficiencia Card&#237;aca Cr&#243;nica. En este art&#237;culo, presentamos una revisi&#243;n de la literatura sobre la fisiopatolog&#237;a y las consecuencias cl&#237;nicas de las alteraciones patol&#243;gicas digestivas de pacientes con insuficiencia card&#237;aca. Las anormalidades estructurales y funcionales del tracto gastrointestinal, como el edema de la mucosa absortiva y el hipercrecimiento bacteriano intestinal, han sido responsabilizadas de las graves consecuencias cl&#237;nicas. Entre ellas destacamos la caquexia card&#237;aca, la activaci&#243;n inflamatoria sist&#233;mica y la anemia. Esas condiciones, aisladamente o de forma combinada, pueden conllevar al empeoramiento de la disfunci&#243;n ventricular preexistente. Aunque actualmente no exista una terap&#233;utica espec&#237;fica dirigida a las alteraciones gastrointestinales asociadas a la insuficiencia card&#237;aca, el entendimiento de las anormalidades digestivas es fundamental para su prevenci&#243;n y para el manejo de las consecuencias sist&#233;micas.</p>
      <p><bold>Palabras clave:</bold> Insuficiencia card&#237;aca/complicaciones, caquexia, anormalidades del sistema digestivo, absorci&#243;n intestinal, anemia</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La Insuficiencia Card&#237;aca (IC) puede ser definida como un s&#237;ndrome cl&#237;nico complejo que proviene de anormalidades card&#237;acas estructurales y/o funcionales, adquiridas o hereditarias, que conllevan al empeoramiento de la capacidad de llenado y eyecci&#243;n ventricular<sup>1</sup>. Constituye un problema cl&#237;nico de extrema importancia, tanto por su alta prevalencia, como por la gravedad de sus manifestaciones cl&#237;nicas. En Brasil, es la tercera causa m&#225;s frecuente de ingresos hospitalarios y la primera causa de ingresos por enfermedad cardiovascular. Seg&#250;n los datos del Datasus, en el 2003 ocurrieron m&#225;s de 350 mil ingresos por IC en el pa&#237;s<sup>2</sup>.</p>
      <p>Las causas m&#225;s comunes de IC son la isquemia mioc&#225;rdica, la hipertensi&#243;n arterial sist&#233;mica, miocardiopat&#237;as y valvulopat&#237;as. En muchos de los casos, sin embargo, la etiolog&#237;a permanece sin conocerse.</p>
      <p>A partir de los estudios pioneros de Frank en 1895, y de Starling en 1918, apareci&#243; el concepto de que las alteraciones en la funci&#243;n de relajaci&#243;n y ejecuci&#243;n del coraz&#243;n son las responsables del desarrollo y de la progresi&#243;n de la IC. Pero en las &#250;ltimas d&#233;cadas, ha quedado claro que la IC es un s&#237;ndrome mucho m&#225;s complejo que involucra no solo, al sistema cardiovascular, sino tambi&#233;n a los sistemas renal, neuroendocrino, inmunol&#243;gico, musculoesquel&#233;tico, hematol&#243;gico y gastrointestinal. Por tanto, las investigaciones han sido desarrolladas para elucidar la fisiopatolog&#237;a de complicaciones sist&#233;micas y proponer un tratamiento que genere una mejor&#237;a en la calidad y en la expectativa de vida de los pacientes que tienen la enfermedad. Entre ellos, destacamos los estudios sobre el compromiso del Tracto Gastrointestinal (TGI) en la IC.</p>
      <p>En esta revisi&#243;n, mostraremos las alteraciones estructurales y funcionales que pueden ocurrir en el TGI de pacientes con IC. A continuaci&#243;n, presentaremos las manifestaciones provenientes del compromiso del TGI, d&#225;ndole un &#233;nfasis particular a la absorci&#243;n inadecuada de constituyentes bacterianos. Finalmente, vamos a abordar las estrategias actuales y bajo investigaci&#243;n para prevenir y/o tratar las alteraciones del TGI asociadas a la IC y sus consecuencias sist&#233;micas.</p>
      <p>El compromiso del TGI en la IC empez&#243; a ser estudiado en la d&#233;cada de 1960 por Davidson et al<sup>3</sup>. Los autores mostraron que pacientes con pericarditis constrictiva presentaban gastroenteropat&#237;a con p&#233;rdida de prote&#237;nas, reversible despu&#233;s de la correcci&#243;n quir&#250;rgica de la lesi&#243;n card&#237;aca. A pesar de los estudios iniciales, solamente en la &#250;ltima d&#233;cada fue que el TGI pas&#243; a ser evaluado m&#225;s detalladamente en la IC.</p>
      <p>
        <bold>Alteraciones gastrointestinales estructurales asociadas a la IC</bold>
      </p>
      <p>Diversas alteraciones estructurales han sido descritas en el TGI de pacientes con IC. En el est&#243;mago, se observaron anormalidades de la mucosa g&#225;strica como est&#225;ndar "en mosaico", ectasia vascular antral, engrosamiento mucoso y &#225;reas de telangiectasias<sup>4,5</sup>.</p>
      <p>En el &#237;leo terminal, colon y sigmoide, fue observado por ultrasonograf&#237;a, el aumento en el grosor de la pared intestinal, lo que sugiere la presencia de edema de asas en los pacientes con IC<sup>6</sup>. Aunque hace mucho que se cree que existe edema de la pared intestinal en los enfermos con retenci&#243;n h&#237;drica importante, &#233;se fue el primer relato de la alteraci&#243;n documentada por examen de imagen realizado <italic>in vivo</italic>. El grosor de la pared del sigmoide parece tener implicaciones cl&#237;nicas, una vez que sus medidas fueron positivamente correlacionadas con la concentraci&#243;n sangu&#237;nea de leucocitos y de Prote&#237;na C Reactiva (PCR) ultrasensible<sup>6</sup>. Esos resultados sugieren que las alteraciones intestinales tienen una relevancia en la inducci&#243;n de la inflamaci&#243;n sist&#233;mica, como veremos posteriormente. Adem&#225;s de espesa, la pared intestinal del intestino delgado presenta un aumento del contenido de tejido col&#225;geno, que es proporcional a la gravedad de la IC<sup>7</sup>. Tal vez como consecuencia de esas alteraciones, la distancia entre la l&#225;mina basal del enterocito y el capilar sangu&#237;neo est&#225; aumentada<sup>7</sup>. Actualmente, se cree que las alteraciones estructurales sean las responsables del empeoramiento de la nutrici&#243;n del enterocito y, por ende, de las anormalidades de la absorci&#243;n intestinal asociadas a la IC.</p>
      <p>
        <bold>Alteraciones gastrointestinales funcionales asociadas a la IC</bold>
      </p>
      <p>Bajo condiciones fisiol&#243;gicas, la circulaci&#243;n espl&#225;ncnica recibe aproximadamente un 25% del d&#233;bito card&#237;aco, haciendo con que el intestino sea uno de los &#243;rganos m&#225;s intensamente perfundidos en reposo<sup>8</sup>. La circulaci&#243;n espl&#225;ncnica es ricamente suplida con los nervios simp&#225;ticos. Por ende, el aumento de la actividad del sistema nervioso simp&#225;tico conlleva a la constricci&#243;n de los vasos de resistencia precapilares y de los vasos de capacitancia pos-capilares, con la reducci&#243;n de la perfusi&#243;n sangu&#237;nea. Las alteraciones vasculares intestinales pueden preceder a las variaciones en la frecuencia card&#237;aca o en la presi&#243;n arterial<sup>9</sup>. Por tanto, incluso las reducciones discretas del d&#233;bito card&#237;aco, pueden conllevar a diferentes grados de isquemia intestinal. En los pacientes con IC avanzada, Krack et al<sup>10</sup> observaron acidosis intramucosa en el est&#243;mago inducida por una ligera actividad f&#237;sica, documentando, por tanto, el aparecimiento de la hipoperfusi&#243;n del TGI. </p>
      <p>Las alteraciones funcionales envuelven, b&#225;sicamente, las anormalidades de la permeabilidad intestinal. La absorci&#243;n intestinal ocurre por v&#237;a transcelular, donde los constituyentes de los alimentos son absorbidos hacia el interior del enterocito y a continuaci&#243;n, hacia el capilar sangu&#237;neo, y por la v&#237;a paracelular, en la cual son absorbidos pasivamente por el paso entre los enterocitos<sup>5</sup>. La v&#237;a de absorci&#243;n paracelular puede ser evaluada por test con la administraci&#243;n de az&#250;cares y el posterior an&#225;lisis de sus concentraciones en la orina<sup>6</sup>. Tanto en el intestino delgado como en los c&#243;lones, la absorci&#243;n paracelular independiente de las prote&#237;nas portadoras, est&#225; aumentada en la IC, sugiriendo una ruptura de la barrera intestinal<sup>5,6</sup>. A su vez, el transporte pasivo mediado por prote&#237;nas portadoras del intestino delgado, se reduce en la IC, lo que sugiere un d&#233;ficit de ATP para la microcirculaci&#243;n<sup>6</sup>.</p>
      <p>En 1996, King et al<sup>11</sup> observaron que los pacientes con IC y caquexia ten&#237;an una reducci&#243;n de la absorci&#243;n intestinal de grasas, cuando se les compar&#243; con los enfermos sin caquexia o con los individuos sanos. La disminuci&#243;n de la absorci&#243;n intestinal estuvo bien documentada en un reciente trabajo, en que se observ&#243; una mayor p&#233;rdida de prote&#237;nas y grasas en la heces de pacientes con IC en clases funcionales III y IV que en aquellos en las clases I y II<sup>7</sup>. Por a&#241;adidura, la reducci&#243;n de la absorci&#243;n intestinal fue m&#225;s evidente en los enfermos con caquexia card&#237;aca. As&#237;, las evidencias sugieren que las alteraciones de la absorci&#243;n intestinal puedan estar involucradas en las etiolog&#237;a de la caquexia asociada a la IC<sup>12</sup>.</p>
      <p>Adem&#225;s de las alteraciones en la absorci&#243;n, los pacientes con IC muestran un alto &#237;ndice de colonizaci&#243;n bacteriana intestinal. Por la t&#233;cnica de FISH (<italic>Fluorescence In Situ Hybridization</italic>), se pudo mostrar que la concentraci&#243;n de bacterias en el biofilme mucoso y la extensi&#243;n de su adherencia a la pared del sigmoide, est&#225;n aumentadas en la IC<sup>6</sup>. Actualmente, se cree que el aumento de la colonizaci&#243;n bacteriana intestinal provenga de las alteraciones estructurales y funcionales del TGI, tal vez en combinaci&#243;n con las anormalidades inmunol&#243;gicas asociadas a la IC.</p>
      <p>Una de las principales consecuencias de las alteraciones gastrointestinales es la absorci&#243;n inadecuada de constituyentes bacterianos, particularmente de endotoxinas, tambi&#233;n conocidas como lipopolisac&#225;ridos<sup>5</sup>. Las endotoxinas son un componente t&#243;xico e inmunog&#233;nico de bacterias Gram negativas. A pesar de las dificultades para la dosificaci&#243;n de las endotoxinas, Niebauer et al<sup>13</sup> mostraron que pacientes con IC y edema, sufren un aumento de la concentraci&#243;n plasm&#225;tica de endoxinas cuando se les compara con los que no tienen edema. Por a&#241;adidura, se observ&#243; tambi&#233;n que, despu&#233;s de la terapia con diur&#233;ticos, ocurre la normalizaci&#243;n de la concentraci&#243;n s&#233;rica de endotoxinas<sup>13</sup>. Ese estudio fue importante para reforzar la hip&#243;tesis vigente de que el edema de la pared intestinal estar&#237;a involucrado en la alteraci&#243;n de la permeabilidad intestinal y en la absorci&#243;n inadecuada de constituyentes bacterianos. El edema intestinal, con sus consecuencias sist&#233;micas, parece caracterizar la principal diferencia, con relaci&#243;n al compromiso del TGI, entre la IC cr&#243;nica estable, y la IC descompensada.</p>
      <p>Hoy por hoy, los lipopolisac&#225;ridos son considerados como uno de los m&#225;s potentes inductores del factor de necrosis tumoral (TNF)-&#945; y de otras sustancias proinflamatorias.</p>
      <p>La importancia del TNF-&#945; en la IC fue descrita inicialmente por Levine et al<sup>14</sup> en 1990. Los autores observaron que pacientes con IC ten&#237;an niveles s&#233;ricos elevados del TNF-&#945; y que esos eran particularmente mayores en aquellos con caquexia. Los hallazgos fueron relevantes en el entendimiento de la fisiopatolog&#237;a de la IC y sus complicaciones, y desencadenaron una gran cantidad de investigaciones en esa &#225;rea<sup>15,16</sup>. Despu&#233;s, qued&#243; claro que el TNF-&#945; es un buen marcador de la gravedad en la IC, correlacion&#225;ndose con la sobrevida, la clase funcional de la IC, el desempe&#241;o card&#237;aco y la concentraci&#243;n s&#233;rica del p&#233;ptido natriur&#233;tico cerebral<sup>17-20</sup>. En estudios experimentales, el aumento de TNF-&#945;, inducido por la administraci&#243;n ex&#243;gena o por el aumento de la expresi&#243;n g&#233;nica, conlleva al fenotipo de la IC, caracterizado por la remodelaci&#243;n ventricular y la reducci&#243;n de la sobrevida<sup>21,22</sup>. Esos hallazgos permitieron llegar a la conclusi&#243;n de que el TNF-&#945; no es solamente un marcador de la gravedad, sino tambi&#233;n un inductor de IC y del empeoramiento del cuadro de disfunci&#243;n ventricular. Posteriormente, fue verificado que, adem&#225;s del TNF-&#945;, otras citocinas tambi&#233;n est&#225;n aumentadas en la IC.</p>
      <p>Las fuentes productoras de citocinas todav&#237;a no se conocen muy bien. El propio miocardio, estructuralmente lesionado, puede expresar y producir niveles aumentados de mediadores inflamatorios, como mol&#233;culas de adhesi&#243;n, TNF-&#945; y IL-6. Los leucocitos circulantes, plaquetas, c&#233;lulas endoteliales, y las c&#233;lulas del pulm&#243;n y del h&#237;gado, tambi&#233;n parecen estar involucrados en la producci&#243;n de citocinas. Es importante remarcar que la respuesta inflamatoria no depende de la etiolog&#237;a de la IC, y ocurre como una v&#237;a final com&#250;n en el portador de IC, independientemente de la causa de la enfermedad<sup>23</sup>. Entre los mecanismos propuestos en la g&#233;nesis de la producci&#243;n de citocinas, destacamos la sobrecarga hemodin&#225;mica, activaci&#243;n neuro-hormonal, presencia de hipoxemia e hipoperfusi&#243;n tisular, oxidaci&#243;n de lipoprote&#237;nas de baja densidad, presencia de autoanticuerpos y estimulaci&#243;n inmunol&#243;gica causada por agentes microbianos, especialmente las endotoxinas<sup>23</sup>.</p>
      <p>Actualmente, se considera que uno de los principales est&#237;mulos para la producci&#243;n de citocinas en la IC, sea la absorci&#243;n de endotoxinas provenientes del TGI<sup>23</sup>. La reducci&#243;n de la producci&#243;n intracelular de citocinas despu&#233;s de una selectiva descontaminaci&#243;n intestinal con antibi&#243;tico, refuerza la hip&#243;tesis<sup>13,24</sup>. Las endotoxinas pueden ser inactivadas por el colesterol s&#233;rico, que forma micelas a su alrededor, aprision&#225;ndolas en su interior. Ese hecho ha sido usado para explicar el por qu&#233; pacientes con IC y colesterol elevado, tienen mejor sobrevida que los que tienen el colesterol reducido. Seg&#250;n la teor&#237;a, mientras mayores sean las concentraciones s&#233;ricas de colesterol, m&#225;s implicar&#237;an en una mayor neutralizaci&#243;n de las endotoxinas<sup>25,26</sup>. Recientemente, fue observado que el aumento de la concentraci&#243;n s&#233;rica de TNF-&#945; induce a las alteraciones adicionales en la barrera epitelial intestinal<sup>9,12</sup>. Se forma, as&#237; un ciclo vicioso en el cual el aumento de la concentraci&#243;n s&#233;rica de una citocina facilita la absorci&#243;n de endotoxinas que, a su vez, inducen la producci&#243;n de varias citocinas.</p>
      <p>Podemos concluir entonces que, la IC induce a anormalidades estructurales y funcionales en el TGI. Una de las consecuencias m&#225;s importantes del compromiso del TGI es la alteraci&#243;n de la absorci&#243;n intestinal, conllevando al compromiso del estado nutricional y a la activaci&#243;n inmunol&#243;gica<sup>9,12</sup>.</p>
      <p>
        <bold>Consecuencias de las alteraciones gastrointestinales asociadas a la IC</bold>
      </p>
      <p>
        <bold>Anemia</bold>
      </p>
      <p>En un metaan&#225;lisis recientemente publicado, que incluy&#243; m&#225;s de 153 mil pacientes con IC, la prevalencia de anemia fue de un 37,2%<sup>27</sup>. Diversos factores pueden estar involucrados en la etiolog&#237;a de la anemia, como la disminuci&#243;n de la ingesti&#243;n alimentaria, la reducci&#243;n de la absorci&#243;n intestinal, p&#233;rdidas sangu&#237;neas por el TGI, anormalidades en la producci&#243;n de hemat&#237;es, empeoramiento de la funci&#243;n renal, inflamaci&#243;n cr&#243;nica, y la hemodiluci&#243;n y el uso de medicamentos<sup>28</sup>. A continuaci&#243;n, vamos a concentrarnos resumidamente, en los factores etiol&#243;gicos involucrados en la g&#233;nesis de la anemia asociada a la IC que provienen, por lo menos parcialmente, de anormalidades del TGI.</p>
      <p>El componente "carencial" parece tener un papel importante en el desarrollo de la anemia. &#201;l proviene de una triade de alteraciones a menudo encontradas en la IC: reducci&#243;n de la ingesti&#243;n alimentaria, disminuci&#243;n de la absorci&#243;n intestinal y p&#233;rdidas sangu&#237;neas por el TGI<sup>28</sup>. Como en otras enfermedades cr&#243;nicas, en la IC existe la activaci&#243;n de mecanismos involucrados en la reducci&#243;n de la absorci&#243;n del hierro. Los lipopolisac&#225;ridos, como la IL-6, inducen la producci&#243;n hep&#225;tica de hepcidina, prote&#237;na de fase aguda que reduce la absorci&#243;n gastrointestinal del hierro, conllevando a la disminuci&#243;n del hierro s&#233;rico, condici&#243;n denominada deficiencia real de hierro. Por a&#241;adidura, la hepcidina reduce la liberaci&#243;n del hierro de las reservas de macr&#243;fagos y hepatocitos, colaborando tambi&#233;n, para la reducci&#243;n del hierro s&#233;rico, en ese caso denominada deficiencia funcional de hierro<sup>29</sup>. Otro factor que puede inducir a la anemia, es la p&#233;rdida sangu&#237;nea por el TGI. Muchos pacientes con IC usan antiagregantes plaquetarios como el &#225;cido acetilsalic&#237;lico y/o anticoagulantes. Esos medicamentos pueden tanto causar lesiones de la mucosa en diversas partes del TGI, como tambi&#233;n facilitar la p&#233;rdida sangu&#237;nea por el tubo digestivo<sup>28</sup>.</p>
      <p>La deficiencia de hierro, adem&#225;s de inhibir la eritropoesis, puede inducir a alteraciones card&#237;acas adicionales, una vez que est&#225; asociada con la activaci&#243;n del sistema nervioso simp&#225;tico, dilataci&#243;n ventricular, alteraciones mitocondriales card&#237;acas y trombocitosis. Las anormalidades asociadas a la deficiencia de hierro, pueden ser reversibles con la administraci&#243;n de hierro. Existen relatos de que la reposici&#243;n de hierro puede incluso, inhibir la producci&#243;n de TNF-&#945;<sup>30,31</sup>.</p>
      <p>Aunque no haya sido sistem&#225;ticamente evaluada en grandes estudios, la deficiencia de hierro ha sido relatada entre 1% a 44 % de los casos, dependiendo de la gravedad de la IC y de la poblaci&#243;n estudiada<sup>32,33</sup>. En los pacientes con IC grave, la deficiencia de hierro fue la causa m&#225;s frecuente de anemia, siendo responsable por un 73% de los casos<sup>34</sup>. Muchos autores creen sin embargo, que despu&#233;s de la correcci&#243;n de la deficiencia de hierro, los pacientes pasen a manifestar el componente de la enfermedad inflamatoria como responsable de la anemia.</p>
      <p>
        <bold>Caquexia</bold>
      </p>
      <p>Otra consecuencia sist&#233;mica proveniente, por lo menos en parte, de las alteraciones del TGI y de la activaci&#243;n inmunol&#243;gica durante la IC, es la caquexia. Actualmente, la caquexia est&#225; considerada como un factor predictivo de reducci&#243;n de la sobrevida de pacientes con IC, independientemente de variables importantes como la edad, clase funcional de la IC o fracci&#243;n de eyecci&#243;n<sup>35</sup>.</p>
      <p>Aunque la fisiopatolog&#237;a de la caquexia asociada a la IC no est&#233; todav&#237;a completamente clarificada, diversos factores han sido responsabilizados de su desarrollo, como la disminuci&#243;n de la ingesti&#243;n alimentaria, la reducci&#243;n de la absorci&#243;n intestinal de nutrientes, el aumento del gasto energ&#233;tico basal y las alteraciones inmunol&#243;gicas y neuroendocrinol&#243;gicas<sup>36,37</sup>.</p>
      <p>La caquexia est&#225; asociada a diversas complicaciones sist&#233;micas, entre las cuales destacamos, las alteraciones card&#237;acas y de la musculatura esquel&#233;tica. Es dif&#237;cil evaluar el compromiso espec&#237;fico de la caquexia sobre el coraz&#243;n, una vez que ella se da en el contexto de una enfermedad inflamatoria cr&#243;nica y como ya se ha dicho antes, la activaci&#243;n inmunol&#243;gica conlleva a importantes efectos perjudiciales en el coraz&#243;n<sup>12</sup>. En nuestro laboratorio, evaluamos los efectos aislados de la restricci&#243;n de la ingesti&#243;n alimentaria sobre los corazones de ratones normotensos e hipertensos. La reducci&#243;n del peso corporal conllev&#243; a la disminuci&#243;n de la masa muscular card&#237;aca, que vino acompa&#241;ada de alteraciones morfol&#243;gicas y ultra estructurales importantes, pero con alteraciones funcionales discretas en los corazones normales<sup>38-41</sup>. A su vez, en el coraz&#243;n hipertrofiado de ratones espont&#225;neamente hipertensos, la restricci&#243;n de la ingesti&#243;n alimentaria indujo tambi&#233;n, adem&#225;s de alteraciones morfol&#243;gicas, al empeoramiento de la funci&#243;n ventricular y mioc&#225;rdica<sup>42-45</sup>. Esos datos muestran que el desarrollo de la caquexia puede conllevar a alteraciones card&#237;acas adicionales y al agravamiento del cuadro preexistente de IC.</p>
      <p>Finalmente en la IC, la combinaci&#243;n de caquexia y activaci&#243;n inmunol&#243;gica puede inducir a anormalidades de la musculatura esquel&#233;tica, con la reducci&#243;n de la capacidad para realizar esfuerzos f&#237;sicos y el empeoramiento de la calidad de vida. La inactividad f&#237;sica, a su vez, trae como resultado, la p&#233;rdida de masa muscular y el agravamiento del cuadro de caquexia<sup>9,12,16,46,47</sup>.</p>
      <p>
        <bold>Tratamiento de las alteraciones del TGI asociadas a la IC</bold>
      </p>
      <p>Abordaremos ahora los posibles objetivos terap&#233;uticos para impedir o reducir las alteraciones gastrointestinales asociadas a la IC y sus consecuencias sist&#233;micas. Como las alteraciones del TGI inducen a una reducci&#243;n de la absorci&#243;n intestinal de nutrientes, es importante realizar una r&#225;pida terapia nutricional para, en el caso de que fuese posible, impedir el desarrollo de la caquexia y si es necesario, tratarla de forma agresiva. La terapia nutricional en la IC es compleja y no forma parte de los objetivos de esta revisi&#243;n.</p>
      <p>Como ya ha sido anteriormente discutido, el edema de la asas intestinales conlleva a la alteraci&#243;n de la permeabilidad intestinal y a la absorci&#243;n de endotoxinas. Por eso, es importante mantener a los pacientes con el menor grado de edema posible. Adem&#225;s de la terapia diur&#233;tica, el bloqueo neuro-hormonal debe ser realizado de acuerdo con las directrices actuales, con el objetivo de mejorar el cuadro de IC.</p>
      <p>La deficiencia de hierro debe ser investigada constantemente y tratada con la administraci&#243;n de hierro por v&#237;a oral o intravenosa. A pesar de algunos estudios experimentales que muestran la reducci&#243;n de la translocaci&#243;n intestinal con la antibioticoterapia, todav&#237;a no ha sido definido si la modulaci&#243;n de la microflora intestinal puede ser &#250;til en el control del proceso inflamatorio sist&#233;mico. Por tanto, la descontaminaci&#243;n intestinal selectiva no est&#225; indicada en la IC<sup>9,12</sup>.</p>
      <p>Como existe una dificultad para evitar la absorci&#243;n inadecuada de constituyentes bacterianos, buscamos bloquear sus efectos sist&#233;micos. En la &#250;ltima d&#233;cada, se realizaron diversos estudios cl&#237;nicos que evaluaron los efectos de varios agentes inmunomoduladores<sup>48</sup>. Entre los f&#225;rmacos con actividad anti-TNF-&#945;, desatacamos el etanercept y el infliximab. En abarcadores estudios cl&#237;nicos, esos agentes tuvieron resultados nulos o empeoraron en la evoluci&#243;n de la IC, siendo, por tanto, contraindicados actualmente<sup>49,50</sup>. Otro inmunomodulador evaluado en la IC fue la pentoxifilina. Entre sus posibles acciones est&#225; la inhibici&#243;n de la s&#237;ntesis de citocinas, particularmente del TNF-&#945;. La pentoxifilina fue testada apenas en peque&#241;os estudios que obtuvieron resultados favorables o nulos<sup>51</sup>. Tambi&#233;n la talidomida, evaluada en peque&#241;os estudios, present&#243; resultados divergentes<sup>48</sup>. Finalmente, estudios preliminares con la administraci&#243;n de inmunoglobulina indicaron resultados positivos, como una mejor&#237;a en la fracci&#243;n de eyecci&#243;n<sup>48</sup>. Actualmente, entre las perspectivas para el futuro, diversos potenciales agentes inmunomodulatorios est&#225;n siendo investigados experimentalmente, como los inhibidores de la activaci&#243;n de c&#233;lulas T, antagonistas de quimiocinas espec&#237;ficas, IL-10, antagonistas de los receptores de la IL-1, inhibici&#243;n de la TACE, inhibici&#243;n de la p38 MAP Kinasa, metotrexato y n-acetilciste&#237;na<sup>23,52</sup>. Finalmente, consideramos que los ejercicios f&#237;sicos puedan tener un papel importante en la modulaci&#243;n de la respuesta inflamatoria exacerbada en la IC<sup>53,54</sup>. De hecho, Adamopoulos et al<sup>55</sup> mostraron que el ejercicio f&#237;sico regular puede reducir la concentraci&#243;n s&#233;rica de TNF-&#945; y de IL-6.</p>
      <p>Como colof&#243;n, podemos decir que en la insuficiencia card&#237;aca ocurren alteraciones estructurales y funcionales del tracto gastrointestinal. Sus consecuencias cl&#237;nicas incluyen un empeoramiento del estado nutricional, la activaci&#243;n inflamatoria sist&#233;mica y la anemia. Esas condiciones, aisladas o combinadas, inducen a alteraciones card&#237;acas y al empeoramiento de la disfunci&#243;n ventricular preexistente. Hoy por hoy, no hay una modalidad terap&#233;utica definida para impedir o reducir las alteraciones gastrointestinales asociadas a la insuficiencia card&#237;aca y sus consecuencias sist&#233;micas.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuve fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
